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Introduction
Thyroid hormone is indispensable for the metabolism of all tissues. The importance of 
thyroid hormone in normal physiology is well illustrated by primary thyroid diseases in which 
abnormal thyroid hormone concentrations affect the function of several organs resulting in a 
variety of clinical symptoms (1). Hypothyroid symptoms include cold intolerance, constipation, 
bradycardia and weight gain. In contrast, patients with hyperthyroidism complain of sweating, 
palpitations and weight loss. These clinical effects of alterations in thyroid state arise from 
changes in thyroid hormone at the cellular level.
Despite adequate restoration of biochemical euthyroidism with replacement therapy with 
levothyroxine (LT4), a substantial amount of patients (~10-15%) with hypothyroidism display 
significant impairment of psychological well-being compared to controls of similar age and 
sex and show decrements in health status (2-4). In addition, many patients report ongoing 
symptoms such as muscle aching and tiredness. The reasons for these observations are still 
unknown. The general focus of this thesis is therefore to explore the cause of persisting 
symptoms in treated hypothyroid patients and to find new biomarkers for thyroid state. 
Thyroid hormone synthesis
Thyroid hormone is synthesised by the thyroid gland, which is located ventrocaudal of 
the thyroid cartilage. Thyroid hormone synthesis is a multi-step process. First, iodide, the 
principal component of thyroid hormone is transported across the basolateral membrane 
of the thyrocyte by the Na/I symporter (NIS). Next, iodide enters the follicular lumen from 
the cytoplasm by the SLC26A4 transporter (Pendrin). In the colloid, iodide (Iˉ) is oxidized 
to iodine (I+) by the enzyme thyroid peroxidase (TPO) and is then condensed onto tyrosine 
residues which reside along the polypeptide backbone of a protein called thyroglobulin. This 
reaction results in either a mono-iodinated tyrosine (MIT) or di-iodinated tyrosine (DIT) 
being incorporated into thyroglobulin. The other synthetic reaction is a coupling reaction, 
where iodotyrosine molecules are coupled together. If two DIT residues couple together, the 
result is the formation of 3,3’,5,5’-tetraiodothyronine (thyroxine; T4). If a DIT and a MIT 
residue are coupled together, the result is the formation of 3,3’,5-triiodothyronine (T3). 
Although T3 is more biologically active than T4, the majority of T3 production (85%) actually 
occurs outside of the thyroid gland.  In peripheral tissues, T3 is produced by  conversion from 
the prohormone T4 by the iodothyronine deiodinases type 1 (D1) and 2 (D2) (Figure 1). D1 
is present in liver and kidney, whereas D2 is present in brain, brown adipose tissue, skeletal 
muscle and the heart. The type 3 deiodinase (D3) is responsible for the degradation of T4 
and T3 to the transcriptionally inactive hormones reverse T3 (3,3’,5’-triiodothyronine) and 
3,3-diiodothyronine (3,3’-T2). D3 is present in brain, skin and placenta. 
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Although the conversion of T3 to 3,5-diiodothyronine (3,5-T2) has not been experimentally 
demonstrated in vertebrates, the most plausible pathway for 3,5-T2 formation is the outer 
ring deiodination of T3 (Figure 1). It is not yet known which deiodinase enzyme catalyses this 
conversion but a likely candidate is D2 (5).
Figure 1. Structures of the principal thyroid hormones and their major pathways of deiodination. 
Hypothalamus-pituitary-thyroid axis
Serum thyroid hormone levels are strictly regulated by the hypothalamus-pituitary-thyroid 
(HPT) axis (6) (Figure 2). Thyroid hormone is secreted in response to thyroid-stimulating 
hormone (TSH), which is synthesized in the pituitary and mediates its effects via binding 
to the TSH receptor. TSH production is stimulated by hypothalamic thyrotropin releasing 
hormone (TRH). The production of TRH and TSH can be downregulated by thyroid hormones 
(negative feedback). Since serum TSH concentrations reflect the pituitary feedback to serum 
concentrations of thyroid hormone, it is used in clinical practice to monitor LT4 treatment. 
However, studies in rodents indicate that different levels of genetic disruption of this feedback 
mechanism (mice with targeted inactivation of both D1 and D2 genes) have increases in serum 
T4 and TSH concentrations, while serum T3 concentrations remain stable (7, 8). This implies 
that the HPT axis is wired to preserve especially serum T3 concentrations (9). 
Thyroid hormone action
The cellular uptake of T4 and T3 is mediated by a number of transmembrane transporters. 
The most important thyroid hormone transporters include the organic anion transporter 
family member OATP1C1 and monocarboxylate transporter (MCT)8 and MCT10 (10).
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Figure 2. The hypothalamic-pituitary-thyroid axis.
Thyroid hormone acts via genomic and non-genomic pathways. Genomic actions of thyroid 
hormone are mediated by binding to nuclear T3 receptors (TRs) which regulate transcription 
of target genes (11). Several receptor isoforms are encoded by the THRA (thyroid hormone 
receptor α) and THRB (thyroid hormone receptor β) genes of which TRα1, TRβ1 and TRβ2 are 
the thyroid hormone binding isoforms (12). Both receptors have a wide expression pattern, 
with a predominance of TRα1 in brain, heart and bone and TRβ1 as the major isoform in 
the liver, kidney and thyroid. TRβ2 is mainly expressed in hypothalamus and pituitary and 
is therefore involved in the regulation of the HPT axis (13). The TRs functions as ligand-
dependent transcription factors. TRs bind to thyroid hormone response elements (TREs) in 
the promoter regions of target genes, thereby regulating gene transcription by the interaction 
with co-activators and co-repressors (12). Many different animal models have been used to 
explore which genes are regulated by thyroid hormone (14-16). 
However, it is largely unknown which genes are regulated by thyroid hormone in human 
tissues. More knowledge of the effects of thyroid hormone on gene expression in different 
tissues would lead to a better understanding of the widespread clinical effects of thyroid 
hormone in the human body. In a previous study of 10 thyroidectomised patients with 
differentiated thyroid carcinoma (DTC) 607 differentially expressed genes in skeletal muscle 
samples on and after 4 weeks off LT4 replacement were detected, of which approximately 60% 
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were positively and approximately 40% were negatively regulated (17). This study also showed 
that the expression of the precursor microRNA (miRNA) pair miRNA-206/ miRNA-133b 
highly differed on thyroid state. MiRNAs are small non-coding RNA molecules, which post-
transcriptionally repress the expression of target genes by binding to the 3’UTR of messenger 
RNA (Figure 3) (18-20). MiRNAs exhibit tissue-specific expression patterns and each miRNA 
may affect the expression of hundreds of target genes. Remarkably, miRNAs are present in the 
circulation and have been associated with a variety of diseases (21, 22). 
Figure 3. A canonical microRNA, lin-4, is processed from its precursor transcript by Dicer, and base pairs 
with a complementary sequence in the 3′UTR of a target, in this case lin-14 mRNA, thereby triggering a 
cis-acting translational repressive activity. (image adapted from Ambros et al (20))
Hypothyroidism
Thyroid autoimmunity is the most common cause of hypothyroidism (Hashimoto’s 
disease). TPO antibodies (TPO-Abs) are present in almost all patients with autoimmune 
hypothyroidism (1). Autoimmune hypothyroidism is commonly accompanied by depressive 
symptoms. A large epidemiological Danish nationwide, prospective cohort study showed that 
various autoimmune diseases including autoimmune thyroid disease (AITD), are associated 
with subsequent lifetime mood disorder diagnosis (e.g. bipolar affective disorder, unipolar 
depression, psychotic depression and other remaining mood disorders) (23). Even subjects 
with thyroid autoimmunity but still with a normal thyroid function have a higher risk to 
develop mood disorders (24). Also offspring of patients with a bipolar disorder have a higher 
prevalence of TPO-Abs, even if they are not affected by the disorder (25). In addition, a higher 
prevalence of AITD has been reported in patients with bipolar disorders, irrespective of the 
usage of lithium (26). Taken together, these associations might imply a shared immune 
pathogenesis for both AITD and mood disorders which needs to be explored. 
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However, after thyroidectomy, cured patients with differentiated thyroid carcinoma (DTC) 
on LT4 replacement therapy have also been shown to have an impaired quality of life (QoL) 
although they are not affected by an autoimmune disease (27, 28). An explanation for this 
impaired QoL might be the inadequacy of LT4 treatment to restore physiological T4 and 
T3 concentrations in serum and tissues (29, 30). In euthyroid patients, approximately 15% 
of circulating T3 is directly secreted by their thyroid gland. Nevertheless, in hypothyroid 
patients, LT4 monotherapy is the standard of care. The peripheral conversion of LT4 to T3 
makes it possible to achieve normal T3 concentrations in patients treated with LT4, albeit with 
the necessity for maintaining T4 concentrations at the higher end of the normal range (31-33). 
Studies in hypothyroid rats have demonstrated that LT4 monotherapy is not able to normalize 
T4 and T3 concentrations in all tissues (34). Supra-physiological serum T4 concentrations had 
to be reached in most tissues to normalize tissue T3 concentrations and the  LT4 dose required 
to normalize thyroid hormone concentrations was different for each tissue. However, addition 
of synthetic T3 (liothyronine) to LT4 treatment regimens is controversial. A meta-analysis of 
11 studies that had been performed so far comparing the effectiveness of T4-T3 combination 
therapy vs LT4 monotherapy, did not find any improvement of symptoms and QoL for T4-T3 
combination therapy (35). It should be mentioned that the wide variation in T4 to T3 dose 
ratio within and between these trials constitutes a potential bias because most studies fail to 
mimic the ratio of T4 to T3 secretion by the thyroid gland under physiological conditions (36). 
Furthermore, synthetic T3 was used in the plain form in all these studies (a reliable slow-
release T3 is currently not (yet) available), resulting in non-physiologic serum T3 peaks (37). 
Substitution with T3 should preferably be performed with a preparation that slowly releases 
T3 to avoid these peaks (38). Also, it remains unknown whether other endogenous thyroid 
hormone metabolites with T3-agonistic or antagonistic activities, like 3,5-T2, might play a 
role in the persisting symptoms and decreased QoL among hypothyroid patients. Recent 
studies have shown that 3,5-T2 concentrations are higher in thyroidectomized patients on LT4 
substitution therapy as compared with healthy controls, suggesting extrathyroidal production 
or conversion (39). 
Finally, several studies have shown that serum TSH, which is currently used to monitor LT4 
treatment, is not always an appropriate marker and that normal serum TSH concentrations in 
patients receiving LT4 reflect only pituitary euthyroidism (40-42). For all these reasons, novel 
markers representing tissue thyroid state are needed.  
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Outline of the thesis
The studies documented in this thesis consist of three major parts. The first part of the thesis 
(chapters 2 and 3) includes 2 studies on the physiological effects of thyroid state on target 
tissues/organs. In chapter 2, the effect of thyroid state on renal concentrating ability was 
studied in DTC patients on and off LT4 treatment. We used serum and urine samples of DTC 
patients because they are subject to severe hypothyroidism before radioactive iodine therapy 
to stimulate radioactive iodine uptake by malignant tissues, whereas they have relatively high 
thyroid hormone concentrations afterwards when receiving substitution therapy with LT4 in 
order to reach TSH suppression. In chapter 3, the effect of thyroid state on the microcirculation 
was studied in other DTC patients on and off LT4 treatment. The microcirculation is the main 
site of oxygen delivery to tissue cells and is essential for the maintenance of cellular life and 
function. The function of the organs is directly dependent on the function of their respective 
microcirculation. The effects of thyroid hormone deficiency on the microcirculation have not 
been well assessed.  
In the second part of the thesis, we explored the link between AITD and mood disorders 
(chapter 4) and studied the association between thyroid hormones and QoL (chapter 5). To 
explore the link between AITD and mood disorders we determined 5 growth and differentiation 
factors that have repeatedly been shown to be abnormally expressed in the circulation of mood 
disorder patients and that are capable of influencing immune and/or neuronal cell growth 
(chapter 4). In chapter 5, we studied the association between extensive thyroid function 
tests, including 3,5-T2 concentrations and T4/T3 ratios, and QoL in athyreotic patients on 
LT4 replacement. We studied patients with DTC, as these patients lack endogenous thyroidal 
T3 secretion after thyroidectomy in the absence of an autoimmune disease.  
In the third part of this thesis (chapters 6 and 7), we searched for new biomarkers of thyroid 
state. Chapter 6 describes an attempt to measure potential miRNAs in serum regulated by 
thyroid state. To study the effects of thyroid state on gene expression in whole blood (mainly 
consisting of TRα expressing leucocytes) we performed next generation RNA sequencing in 
DTC patients on and off LT4 treatment (chapter 7).
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thyroid hormone
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Effects of thyroid hormone on 
renal concentrating ability
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J.W. Burger, W. Edward Visser, Ewout J. Hoorn, Robin P. Peeters
Eur Thyroid J. 2017; 6:238–242 
Chapter 2
22 | Chapter 2
Abstract
Background: Hypothyroidism has been associated with impaired urinary concentrating 
ability. However, previous reports on thyroid hormone and urinary concentrating ability in 
humans only studied a limited number of patients with autoimmune thyroid disease or used 
healthy controls instead of paired analysis within the same patients.
Objective: To study the urinary concentrating ability in athyreotic patients with differentiated 
thyroid cancer on and off levothyroxine treatment as they are exposed to different thyroid 
states as part of their treatment in the absence of an autoimmune disease.
Design and methods: We studied 9 patients (mean age of 42.7 years) during severe 
hypothyroid state (withdrawal of levothyroxine before radioactive iodine therapy) and TSH 
suppressed state (on levothyroxine therapy). At these two points, serum and urine samples 
were collected after 14 hours of overnight thirsting. 
Results: Serum and urine osmolality were not significantly different between on and off 
levothyroxine treatment. Serum creatinine levels were significantly higher in patients off 
vs. on levothyroxine treatment (87.0 µmol/l vs. 71.0 µmol/l respectively; p= 0.044) and, 
correspondingly, the estimated glomerular filtration rate (eGFR) was significantly lower (89.6 
ml/min vs. 93.1 ml/min respectively; p= 0.038). 
Conclusion: Short-term, severe hypothyroidism has no effect on urinary concentrating 
ability. Our study confirms the well-known effects of thyroid hormone on serum creatinine 
concentrations. 
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Introduction
Thyroid hormone (TH) is indispensable for the metabolism of all tissues. The importance of 
TH in normal physiology is well illustrated by primary thyroid diseases in which abnormal TH 
concentrations affect the function of several organs resulting in a variety of clinical symptoms 
(1). 
The ability to conserve water during periods of water deprivation is an important function 
of the kidney. Fluid deprivation increases serum osmolality and thereby causes a release of 
the antidiuretic hormone (arginine vasopressin (AVP)). In turn, in the principal cells of the 
collecting duct, vasopressin inserts pre-formed vesicles with the water channel aquaporin-2 
into the apical plasma membrane to allow water reabsorption (2). The counter current 
mechanism creates the osmotic driving force for water reabsorption in the collecting duct. 
Hypothyroidism has been associated with impaired urinary concentrating capacity in 
animals and humans (3-6). Short-term hypothyroidism in rats results in a diminished 
medullary osmotic driving force for passive water movement across the collecting duct. 
This was associated with a significant decrease in the medullary sodium potassium chloride 
cotransporter type 2  (NKCC2) (4). The impaired maximal urinary concentrating capacity in 
these rats with moderate hypothyroidism was readily reversed with TH replacement. On the 
other hand, long term hypothyroidism in rats resulted in an impaired urine dilution capacity 
after water loading  as a result of the non-osmotic release of vasopressin (3). This defect was 
reversed by administering a vasopressin receptor antagonist.
Only a few studies on the urinary concentrating defect in hypothyroidism have been performed 
in patients with autoimmune thyroid disease (5, 6). A small study (n=4) of patients with 
hypothyroidism revealed a urinary concentrating defect after 16 hours of water deprivation (5). 
After adequate treatment with levothyroxine (LT4), this defect was corrected. Another study 
found similar defects in myxoedema patients (n=10) compared to healthy control subjects 
(n=15) after 16 hours of water restriction (6). Treatment of a small group of these patients 
(n=3) showed no improvement in urinary concentrating capacity. These studies on TH and 
urinary concentrating ability in humans only studied a very limited number of patients (5) or 
used healthy controls instead of paired analysis within the same patients (6). Furthermore, 
detailed thyroid function tests were not performed.  
The aim of this study was to extend the existing studies by investigating the urinary 
concentration ability for the first time in athyreotic patients, before and after LT4 treatment. 
We therefore studied patients with differentiated thyroid cancer (DTC), as they are exposed 
to different thyroid states as part of their treatment in the absence of autoimmune disease. 
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Subjects and methods
DTC patients, 18-65 years old, were recruited from the outpatient clinic of the Erasmus 
Medical Center Rotterdam, between November 2014 and October 2015. Initial therapy 
consisted of total thyroidectomy. Patients were eligible for inclusion if they were scheduled for 
treatment with radioactive iodine (RAI); did not use drugs interfering with TH metabolism 
or drugs influencing urinary concentration capacity (e.g, diuretics, lithium, non-steroidal 
anti-inflammatory drugs); did not have a urinary tract infection; had no history of diabetes 
insipidus, diabetes mellitus or adrenal insufficiency; and had an estimated glomerular 
filtration rate (eGFR) > 60 mL/min per 1.73 m2. Patients were instructed to restrain from 
water and food for 14 hours before their outpatient visit on two different occasions. The 
first measurement was scheduled after four weeks of TH withdrawal (before RAI therapy, to 
stimulate radioactive iodine uptake by malignant tissues) and the second a few months after 
restoring euthyroidism/ TSH suppression. Our primary endpoint was the difference in urine 
osmolality between LT4 withdrawal and treatment. Peripheral blood samples and spot urine 
samples were obtained from all participants. 
The Medical Ethics Committee of the Erasmus Medical Center approved the study protocol 
(MEC-2014-134) and written informed consent was obtained from all study participants.
Laboratory measurements
Serum Free T4 (FT4) (reference range 11.0-25.0 pmol/l), total T4 (reference range 58.0-
128.0 nmol/l) and total T3 (reference range 1.4-2.5 nmol/l) concentrations were measured 
by chemo luminescence assays (Vitros ECI Immunodiagnostic System; Ortho-Clinical 
Diagnostics, Rochester, MI). Serum TSH (reference range 0.4-4.3 mU/l) was measured by 
immunometric assay (Immulite 2000 XPi, Siemens, Den Haag, the Netherlands). Serum 
and urine osmolality were measured by OM 6050 Osmo Station from A. Menarini Diagnostic 
and serum sodium, potassium, urea, creatinine, chloride and glucose concentrations were 
measured by Roche/Hitachi cobas c systems. The eGFR was computed automatically with 
the Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI). Sodium, urea 
and creatinine concentrations were also measured in urine samples by Roche/Hitachi cobas 
c systems. 
Statistical analysis
Based on the previous studies (5, 6), we postulated that a study in 10 patients on and off LT4 
treatment would be of sufficient sample size to find a significant difference in urine osmolality. 
Data were expressed as median with 25th and 75th percentiles. For paired analysis between 
patients on and off LT4 treatment the Wilcoxon signed rank test was used. We used SPSS 20.0 
for Windows (SPSS, Inc., Chicago, IL, USA). The spearman rank correlation coefficient was 
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calculated to evaluate the correlation between urine osmolality and age and thyroid function 
tests off and on LT4 treatment. A p value < 0.05 was considered as statistically significant. 
Results
We included 10 patients in the study. However, one of them started on treatment with a 
diuretic after the first visit and was therefore excluded. Nine patients with a mean age of 42.7 
years (range 24-57 years) were analysed (Table 1). As expected, thyroid function tests were 
significantly different on and off LT4 treatment (Table 2), reaching very low levels of FT4 
(median 1.7 pmol/l) off LT4. Serum creatinine levels were significantly higher (87.0 vs. 71.0 
µmol/l, p= 0.044) and the eGFR was significantly lower in hypothyroid state than in LT4 
treated state (89.6 ml/min vs. 93.1 ml/min respectively; p= 0.038). Serum glucose levels were 
significantly lower during hypothyroidism (4.8 vs 5.3 mmol/l, p= 0.011). Serum sodium and 
chloride levels were significantly higher during LT4 treatment than during hypothyroidism 
(143 vs. 141 mmol/l; p= 0.011 and 104.0 vs 99.0 mmol/l; p= 0.007, respectively), while serum 
osmolality remained similar (287.0 on LT4 vs. 282.0 mOsm/kg off LT4; p= 0.09). 
Table 3 shows that urinary osmolality was not significantly different between patients on and 
off LT4 treatment (765.0 vs. 630.0 mOsm/kg, respectively; p= 0.17). Figure 1 shows the changes 
in urinary osmolality within each patient. There was also no significant difference in sodium, 
urea and creatinine levels in the urine samples. There was no correlation between urinary 
osmolality and age, TSH, FT4, total T4 and total T3 levels neither during hypothyroidism nor 
during LT4 treatment (data not shown). 
Table 1. Characteristics of study participants
Sex N(%)
   Male
   Female
4 (44.4)
5 (55.6)
Age (years), mean (±SD) 42.7 (± 11.0)
Time between tests(days), median (25th-75th percentile) 124 (91-161)
Dose LT4 (µg), mean (range) 204.2 (150-325)
Dose LT4 (µg/ kg), mean (range) 2.27 (1.6-3.1)
Diagnosis N(%)
   Papillary thyroid cancer
   Follicular thyroid cancer
7 (82.5) 
2 (12.6)
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Table 2. Changes in thyroid function tests and serum electrolytes, creatinine and osmolality off and on 
LT4 treatment. 
Off LT4 LT4 treated P value
TSH (mU/l) 68.4 (42.0-102.5) 0.049 (0.005-0.57) 0.008
FT4 (pmol/l) 1.7 (1.2-3.4) 24.1 (21.5-25.3) 0.008
Total T4 (nmol/l) 17.0 (14.0-28.0) 146.0 (132.0-170.5) 0.008
Total T3 (nmol/l) 0.7 (0.6-1.0) 2.1 (2.0-2.3) 0.008
Creatinine (µmol/l) 87.0 (76.5-92.0) 71.0 (67.5-89.5) 0.044
eGFR (ml/min) 89.6 (66.4-93.1) 93.1 (85.8-103.8) 0.038
Urea (mmol/l) 4.6 (3.7-5.1) 4.8 (4.1-5.2) 0.21
Sodium (mmol/l) 141.0 (138.5-141.5) 143.0 (142.0-144.5) 0.011
Glucose (mmol/l) 4.8 (4.5-5.1) 5.3 (4.9-5.6) 0.011
Potassium (mmol/l) 4.3 (4.2-4.5) 4.4 (4.1-4.6) 0.5
Chloride (mmol/l) 99.0 (97.5-101.5) 104.0 (102.5-104.5) 0.007
Osmolality (mOsm/kg) 282.0 (279.0-284.0) 287.0 (281.5-288.0) 0.09
Data are expressed as median (25th-75th percentile).
Table 3: Changes in urine concentrations and osmolality
Off LT4 LT4 treated P value
Osmolality (mOsm/kg) 630.0 (535.0-812.0) 765.0 (613.0-794.0) 0.17
Sodium (mmol/l) 84.0 (54.5-146.0) 141.0 (95.5-157.5) 0.21
Creatinine (mmol/l) 17.2 (12.3-28.5) 13.7 (12.1-20.6) 0.09
Sodium/ creatinine ratio 5.1 (1.9-10.8) 11.0 (5.1-12.0) 0.26
Urea (mmol/l) 258.0 (190.0-383.0) 328.0 (274.0-439.0) 0.09
Data are expressed as median (25th-75th percentile). 
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Figure 1. Changes in urine osmolality off and on LT4 treatment. Each line between two dots represents 
a patient.
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Discussion
In this prospective study in athyreotic DTC patients there was neither a significant difference 
in urine osmolality nor in serum osmolality on and off  LT4 treatment after a water and 
food deprivation test of 14 hours. Since we could not detect an impairment of urinary 
concentrating ability during severe hypothyroidism in our patients, we did not assess AVP 
and copeptin concentrations, a stable pre-pro-hormone of AVP.  Our findings are in contrast 
with previously published studies in rats (4) and humans (5, 6). In these previous studies on 
urinary concentrating ability in humans, detailed thyroid function tests were not performed. 
The severity of hypothyroidism was predominantly based on clinical characteristics, which is 
not very precise (7). In the current study, we confirmed severe hypothyroidism biochemically 
with a median TSH level of 68 mU/l, and correspondingly low levels of FT4, Total T4 and T3. 
Whereas previous studies were performed in patients with prolonged signs of hypothyroidism 
(i.e. myxedema), hypothyroidism in the current study existed only for four weeks. Although 
we cannot exclude that there would have been an impaired urinary concentrating ability 
after prolonged hypothyroidism, the current study excludes important acute consequences of 
altered thyroid hormone status. 
Another speculative explanation for our findings could be that our patients were treated with 
relatively high dosages of LT4 to establish TSH suppression (median TSH concentration 
of 0.049 mU/l) because of their thyroid cancer. Although our patients were not overtly 
thyreotoxic, high TH levels are associated with a hyperdynamic circulation including increased 
cardiac output and blood pressure and decreased systemic vascular peripheral resistance 
(8). These systemic hemodynamic alterations are known to be associated with increased 
renal hemodynamics and urine flow which might have decreased the urine osmolality in 
our LT4 treated patients (9). This mechanism is supported by Wang et al, who observed 
in hyperthyroid rats a significant increase in solute excretion in the presence of an AVP 
independent downregulation of aquaporin water channels (10). In healthy human subjects, 
water deprivation causes the plasma osmolality to rise above 280–290  mOsmol/kg, which 
leads to the release of AVP into the circulation. This results in increased water retention with 
a rise in urine osmolality to a maximum of 1000–1200 mOsmol/kg and restoration of plasma 
osmolality toward the reference range (11). Since the median urine osmolality was lower than 
1000 mOsmol/kg in both thyroid states in our patients, one could speculate that there was a 
concentrating defect in both thyroid states and we were therefore not able to find a statistical 
significant difference in urine osmolality.
Serum creatinine levels were significantly higher in our patients during hypothyroidism 
than during LT4 treatment and, correspondingly, eGFR was significantly lower during 
hypothyroidism. This is in line with several case reports and case series (12-14). Previous 
detailed studies have shown that the changes in serum creatinine reflect actual changes in 
GFR instead of alterations in creatinine metabolism (15-17).  
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A limitation of our study is the small number of patients, which is a consequence of the steadily 
growing number of DTC patients that are treated with RAI after preparation with recombinant 
TSH instead of LT4 withdrawal (18). A second limitation is the low iodine diet which patients 
had to adhere to in order to increase the effectiveness of RAI treatment. Although this diet is 
different from a “low-sodium” diet, any foods containing iodized salt and sea salt were not 
allowed (19). Therefore, we cannot exclude that this diet might have influenced the sodium 
and chloride levels and hence osmolality in our patients during hypothyroidism. Indeed, the 
significantly lower serum sodium (without development of hyponatremia) and chloride levels 
and the decreased urinary sodium/ creatinine ratio off LT4 therapy, thus during the low iodine 
diet, support this notion. Similar results have been reported by Vannucci et al, who also showed 
significantly lower serum sodium levels off LT4 prior to ablative RAI treatment without any 
correlation between serum TSH and sodium levels, suggesting that the reduction in sodium 
levels is unrelated to the hypothyroid status (20). Finally, our study had an outpatient design 
which precludes strict control of adherence to the water deprivation protocol. However, in 
general, an expectedly adequate serum osmolality was observed, indicating adequate water 
deprivation.
In conclusion, although previous studies have shown an impaired urinary concentrating ability 
in patients with myxedema, we did not find any evidence for impaired urinary concentrating 
ability in patients with short-term but severe hypothyroidism. 
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Abstract
Objective: Normal thyroid hormone (TH) levels are required to maintain cardiovascular 
function. Changes in thyroid state affect global hemodynamic parameters, but it is less clear 
if and how it affects the microcirculation. The direct relationship between TH effects on 
macrocirculation and microcirculation has never been studied. We report a full integrated 
assessment of macrocirculation and microcirculation in patients with different thyroid states. 
Design and methods: We studied 10 thyroidectomized patients (4 males) on and after 4 
weeks off levothyroxine replacement. Macrocirculation was assessed by measuring standard 
hemodynamic parameters and transthoracic echocardiography. Peripheral perfusion was 
documented by measuring the body temperature gradient and performing transcutaneous 
oximetry and near-infrared spectroscopy. Using an Incident Dark Field Imaging based 
handheld microscope the sublingual (central) microcirculation was quantified. 
Results: Heart rate, pulse pressure, end diastolic volume and stroke volume significantly 
decreased, while median systemic vascular resistance increased during hypothyroidism. 
Forearm to-fingertip skin-temperature gradient was significantly higher and the peripheral 
perfusion index was significantly lower during hypothyroidism. Parameters of the sublingual 
microcirculation did not differ between thyroid states.
  
Conclusion: Our study confirms several well-known effects of TH on cardiovascular function. 
In addition, we observed that hypothyroidism had profound effects on peripheral perfusion, 
but not on central microcirculation, which may be explained as an adaptive mechanism for the 
reduced thermogenesis. Together, our studies reinforce that TH exerts its well-known clinical 
effects on cardiovascular systems through different physiologic mechanisms.
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Introduction
Thyroid hormone (TH) affects virtually all tissues and cells in the body. Prominent features 
of thyrotoxicosis include palpitations and heat intolerance, while hypothyroidism is 
accompanied by bradycardia and cold intolerance. These clinically well-recognized features of 
abnormal TH levels highlight the important effects of TH on normal cardiovascular function. 
Triiodothyronine (T3), the physiologically active form of TH, controls the inotropic properties 
of the myocardium, cardiac growth and vascular function via genomic and non-genomic 
actions (1-4). 
TH effects on the heart and peripheral vasculature include decreased systemic vascular 
resistance (SVR) and increased resting heart rate (HR), left ventricular contractility, and 
blood volume (5). As a corollary, hypothyroidism results in bradycardia, decreased ventricular 
filling and cardiac contractility, which together decreases cardiac output. 
Although effects of TH on the macrocirculation have been studied extensively, much less is 
known on the effects of TH on the microcirculation in humans (4-6). The microcirculation 
is the last step of oxygen delivery to tissues and cells and is, therefore, essential for the 
maintenance of cellular life and function. The microcirculation can be defined as vessels 
smaller than 100 microns, i.e., arterioles, capillaries and venules and facilitates fine-tuning of 
perfusion to meet local oxygen requirements (7). Microcirculatory derangements with severe 
consequences have been shown in sepsis, hypovolemia and cardiac failure (8, 9). Effects of TH 
on the microcirculation have been demonstrated in a hamster cheek pouch model (10). The 
addition of NG-nitro-L-arginine methyl-ester (L-NAME), which is an inhibitor of nitric oxide 
(NO) synthase, counteracted the T3-induced dilation, suggesting that the effects of T3 on the 
in vivo microcirculation appear to be mediated by NO through a non-genomic mechanism of 
action (10). 
In humans, peripheral microcirculation can be assessed by measuring the body temperature 
gradient and performing transcutaneous oximetry and near-infrared spectroscopy (NIRS), 
while central microcirculation can be studied with handheld video-microscopes (11, 12). 
Previous studies have documented the impact of thyroid state on various parameters 
of macrocirculation and microcirculation (13, 14). However, none of the studies have 
simultaneously assessed macrocirculation and microcirculation. Therefore, a direct 
comparison of the effects of TH on macrocirculation and microcirculation is currently lacking. 
The aim of this study was to perform a full integrated assessment of macrocirculation and 
microcirculation with well-established and state-of-the-art tools in athyreotic patients off and 
on levothyroxine (LT4) replacement therapy.
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Subjects and methods
Patients with differentiated thyroid cancer (DTC), 18-70 years old, were recruited from the 
outpatient clinic of the Erasmus Medical Center Rotterdam, between June 2015 and March 
2016. Initial therapy consisted of total thyroidectomy. Patients were eligible for inclusion if 
they were scheduled for ablation with radioactive iodine (RAI), did not have heart failure or 
drugs interfering with TH metabolism. The first measurement was scheduled after four weeks 
off LT4 (i.e. LT4 withdrawal before RAI ablation) and the second measurement after about 3 
months on LT4 replacement therapy once TSH-suppression was reached. The Medical Ethics 
Committee of the Erasmus Medical Center approved the study protocol (MEC-2014-489) and 
written informed consent was obtained from all study participants.
Laboratory measurements
Serum free T4 (FT4), total T4 and total T3 concentrations were measured by chemo 
luminescence assays (Vitros ECI Immunodiagnostic System; Ortho-Clinical Diagnostics, 
Rochester, MI). Serum TSH was measured by immunometric assay (Immulite 2000 XPi, 
Siemens, Den Haag, the Netherlands). Creatine kinase (CK), CK-MB,  lactate, and aspartate 
aminotransferase (AST) were measured by Roche/Hitachi cobas c501. N-terminal-pro-
B-type natriuretic peptide (NT-proBNP) was measured by an electrochemiluminescence 
immunoassay (Cobas e 601/602).
Macrocirculatory function
Transthoracic echocardiography using an iE33 Ultrasound System (Philips Healthcare, 
Amsterdam, the Netherlands) was performed by experienced technicians who were blinded 
to the thyroid state of the subjects. We assessed left ventricular end diastolic volume (EDV) 
and end systolic volume (ESV) and left atrial volume with biplane Simpson’s method (TomTec 
Cardiac Performance Analysis ©, Munich, Germany). Stroke volume (SV = EDV - ESV), cardiac 
output (CO = HR x SV/1000) and ejection fraction (EF = 100 x (EDV - ESV/EDV)) were 
subsequently calculated. Mitral inflow velocity was derived from the pulsed-wave Doppler in 
the apical four-chamber view: early transmitral inflow (E) velocity, its decelerating time (DET) 
and late transmitral flow (A) velocity were assessed and then the E/A ratio was calculated. By 
using pulsed-wave tissue Doppler image (TDI), early diastolic (E′) mitral annular velocity was 
obtained at the septal mitral annulus level in the apical four-chamber view with septal annulus 
movement aligned with the sample volume line, and the E/E′ ratio was derived.
We assessed systolic blood pressure (SBP) and diastolic blood pressure (DBP) and calculated 
mean arterial blood pressure (MAP) and pulse pressure (PP = SBP - DBP). The SVR was 
calculated by the formula: 80 x (MAP - right atrial pressure)/CO. Cardiac conduction times 
were measured with a 12-lead electrocardiogram (ECG).
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Peripheral microcirculatory function
Capillary refill time (CRT) was assessed, which is defined as the time required for the nail bed 
to regain its color after pressure has been applied to cause blanching. 
Forearm to-fingertip skin-temperature gradient (Tskin-diff) has also been used as an index 
of peripheral circulation (15). Tskin-diff is obtained with two skin probes (Hewlett Packard 
21078A) attached to the index finger and on the radial side of the forearm, midway between 
the elbow and the wrist. When vasoconstriction decreases finger-tip blood flow, finger skin 
temperature decreases, and Tskin-diff increases (11). A Tskin-diff threshold of 0 °C for 
initiating vasoconstriction and of 4 °C for severe vasoconstriction have been suggested (16). 
The peripheral perfusion index (PFI) was derived from the photoelectric plethysmographic 
signal of the finger pulse oximeter. This noninvasive tool uses two wavelengths of light (red 
and infrared) that are transmitted through the distal phalanx of the index finger, resulting in 
the display of a pulsatile photoplethysmographic waveform. The PFI is calculated as the ratio 
between the pulsatile component (arterial compartment) and the non-pulsatile component 
(others tissues) of the light reaching the detector of the pulse oximeter. A PFI of 1.4 or lower 
has been found to be correlated best with hypoperfusion in critically ill patients (11). 
NIRS uses the principles of light transmission and absorption to measure the concentrations 
of hemoglobin and oxygen saturation (StO2) noninvasively in tissues (11). NIRS provides 
a global assessment of oxygenation in all vascular compartments (arterial, venous, and 
capillary).  An inSpectra tissue spectrometer model 650 with a 15-mm probe was placed over 
the thenar eminence to measure StO2.
Assessment of the sublingual/central microcirculation
We used Incident Dark Field (IDF) technology (CytoCam, Braedius Medical, Amsterdam, 
NL) to visualise the sublingual microcirculation (17). In brief, it consists of a handheld video 
microscope that emits stroboscopic green light (530 nm) from an outer ring at the end of a 
probe, which is absorbed by haemoglobin. Thus, a negative image of moving red blood cells is 
transmitted back through the isolated optical core of the probe toward a charge coupled device 
camera. We adhered to the recommendations from an expert panel on how to evaluate the 
microcirculation using SDF imaging (18). 
At each time point, clips at 3 different sublingual sites yielding at least 20 sec of stable video 
per site were recorded. All clips were stored under a random number, which were analysed 
by one trained and blinded observer using dedicated software (AVA 3.0, Microvision Medical, 
NL). Microvascular flow index (MFI), total vessel density (TVD), perfused vessel density 
(PVD) and proportion of perfused vessels (PPVs) were determined for every patient at the two 
different time points. All scores have been validated previously (19). For PPV and PVD, vessel 
density was calculated as the number of vessels crossing 3 horizontal and 3 vertical equidistant 
lines, spanning the screen divided by the total length of the lines. Perfusion at each crossing 
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was then scored semi-quantitatively as follows: 0 = no flow (no flow present for the entire 
duration of the clip), 1 = intermittent flow (flow present <50% of the duration of the clip), 2 = 
sluggish flow (flow present >50% but <100% of the duration of the clip or very slow flow for 
the entire duration of the clip), and 3 = continuous flow (flow present for the entire duration 
of the clip). PVD was calculated as the number of crossings with flow scores greater than 1. 
PPV was calculated as the proportion of crossings with flow scores greater than 1 divided by 
the total number of crossings. Each score was determined for small microvessels with a cut-off 
diameter of 25 µm. In previous studies, intra-observer variability ranges between 2.5 and 9.3% 
for PVD and between 0 and 4.5% for PPV and inter-observer variability ranges between 3.0 
and 10.1% for PVD and between 0 and 10% for PPV (19). MFI was based on the determination 
of the predominant type of flow in 4 quadrants. MFI is the sum of these flow scores divided 
by the number of quadrants in which the vessel type is visible. For each time point and each 
patient, all scores were averaged.
Statistical analysis
Data were expressed as median with inter quartile range (IQR). For paired analysis between 
patients on and off LT4 treatment, the Wilcoxon signed rank test was used. We used SPSS 20.0 
for Windows (SPSS, Inc., Chicago, IL, USA). A p value < 0.05 was considered as statistically 
significant. Since most parameters were interrelated we did not correct for multiple testing.
Results
The baseline characteristics of the 10 included patients are shown in Table 1. As expected, all 
thyroid function tests were significantly different off and on LT4 treatment (Table 2), reaching 
deeply hypothyroid levels in patients off LT4. CK and ASAT levels were significantly higher, 
while NT-proBNP levels were significantly lower off LT4 treatment.
Table 1. Characteristics of study participants
Sex N(%)
   Male
   Female
4 (40.0)
6 (60.0)
Age (years) 43.0 (30.2-55.8)
Time between tests (weeks) 12.2 (11.0-15.9)
Dose LT4 (µg) 187.5 (150.0-225.0)
Dose LT4 (µg/kg) 2.1 (1.8-2.6)
BMI (kg/m²) 28.0 (23.0-31.8)
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Table 2. Changes in thyroid function tests and in several serum biomarkers of organ function off and on 
LT4 treatment
Reference range Off LT4 On LT4 P value
TSH 0.4-4.3 mU/L 99.8 (67.0-144.0) 0.07 (0.01-0.24) 0.005
FT4 11.0-25.0 pmol/L 1.3 (0.9-1.9) 32.0 (22.8-35.9) 0.005
Total T4 58.0-128.0 nmol/L 13.0 (6.5-18.5) 163.0 (134.0-185.5) 0.008
Total T3 1.4-2.5 nmol/L 0.63 (0.42-0.9) 1.98 (1.8-2.2) 0.005
Lactate 0.5-1.7 mmol/L 1.70 (1.4-1.8) 1.45 (1.0-1.6) 0.085
CK Males < 171, females < 145 U/L 185.0 (83.8-493.5) 106.0 (52.5-196.0) 0.005
CK-MB Males < 7.6, females < 4.7 µg/L 3.5 (2.1-5.9) 2.2 (1.4-3.5) 0.075
ASAT Males < 35, females < 31 U/L 43.0 (24.0-52.5) 23.0 (17.8-35.5) 0.025
NT-ProBNP  < 15.0 pmol/L 1.0 (1.0-1.5) 6.0 (2.5-8.5) 0.012
Data are expressed as median (IQR). 
Global hemodynamic parameters are shown in Table 3. Heart rate, systolic blood pressure 
and pulse pressure were significantly lower during hypothyroidism. Echocardiography 
revealed that EDV, left atrial volume, CO and SV were significantly smaller and that SVR 
was significantly higher in patients off LT4 (Figure 1). Hypothyroidism caused a significant 
reduction of peak velocity at early mitral inflow (E-top), while E/A ratio, E/E’ and DET were 
not significantly different off and on LT4 treatment (Table 4). 
Table 3. Changes in global hemodynamic parameters and QTc off and on LT4 treatment
Off LT4 On LT4 P value
Heart rate (beats/min) 53.5 (46.8-64.8) 65.5 (58.3-69.8) 0.017
Systolic blood pressure (mmHg) 128.5 (116.0-140.0) 133.0 (127.0-141.8) 0.032
Diastolic blood pressure (mmHg) 85.5 (74.5-91.5) 79.0 (73.0-82.8) 0.24
MAP (mmHg) 100.0 (87.7-108.4) 95.8 (91.0-102.9) 0.80
Pulse pressure (mmHg) 46.5 (38.3-50.3) 55.0 (53.0-60.5) 0.005
Cardiac output (l/min) 3.6 (3.2-4.2) 5.1 (4.0-5.8) 0.005
SVR (dynes-sec/cm-5) 1972 (1730-2409) 1626 (1302-1827) 0.007
Ejection fraction (%) 57 (50-58) 56 (51-61) 0.65
SpO2 (%) 97.5 (96.0-100.0) 97.5 (96.8-99.0) 0.34
QTc (msec) 390.5 (372.0-404.3) 385.5 (372.3-412.8) 0.29
Data are expressed as median (IQR). MAP, mean arterial pressure; SVR, systemic vascular resistance; 
SpO2, peripheral oxygen saturation.
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Table 5 shows the central microcirculation and peripheral circulation parameters. The Tskin-
diff was significantly higher during hypothyroidism, which was driven by lower temperatures 
measured on the finger compared with the forearm. The PFI was significantly lower during 
hypothyroidism, but StO2 was unchanged. Video-assisted assessment of the sublingual 
microcirculation did not reveal differences between patients off and on LT4 treatment. 
To assess if the changes in peripheral perfusion resulted from macrocirculatory changes, 
we sought to correlate the individual changes in microcirculatory and macrocirculatory 
parameters. No correlation was observed, suggesting that TH-dependent microcirculatory 
changes are independent of the macrocirculation (data not shown).
Table 4. Doppler-echocardiographic parameters off and on LT4 treatment.
Off LT4 On LT4 P value
E-top (cm/sec) 0.58 (0.42-0.68) 0.71 (0.51-0.82) 0.028
E/A ratio 1.38 (0.6-2.0) 1.31 (0.8-1.8) 0.22
E/E’ ratio 8.4 (6.9-9.6) 8.9 (7.9-9.9) 0.48
DET (msec) 195.0 (175.0- 265.0) 195.5 (168.8-264.5) 0.54
E-top, early transmitral inflow velocity; A, late transmitral flow velocity;  E′, early diastolic mitral annular velocity; DET, 
decelerating time. Data are expressed as median (IQR).
Table 5. Parameters of the sublingual (central) microcirculation and of peripheral circulation off and on 
LT4 treatment. 
Off LT4 On LT4 P value
Sublingual microcirculation
TVD (mm/mm2) 17.2 (15.7-19.6) 16.9 (14.4-20.4) 0.8
PVD (mm/mm2) 16.5 (13.7-18.3) 15.0 (13.7-18.6) 0.96
PPV (%) 91.3 (86.3-96.8) 91.9 (82.3-97.0) 0.96
MFI 2.67 (2.4-3.0) 2.75 (2.6-2.9) 0.59
Peripheral circulation
StO2 (%) 74.5 (70.0-83.3) 78.0 (73.5-81.3) 0.48
PFI (%) 1.7 (0.95-3.7) 2.9 (1.7-5.1) 0.037
Tskin-diff (°C) 2.75 (-0.02-5.3) 1.1 (-1.0-3.6) 0.047
CRT (sec)* 4.0 (3.0-4.8) 3.0 (3.0-4.6) 1.0
Data are expressed as median (IQR). TVD, total vessel density; PVD, perfused vessel density; PPV, proportion of 
perfused vessels; MFI, microvascular flow index; StO2, tissue oxygen saturation; PFI, peripheral perfusion index;  Tskin-
diff, Forearm to-fingertip skin-temperature gradient; * Capillary refill time (CRT) was assessed in 9 patients because one 
patient had artificial nails.
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Figure 1. Changes in several echocardiographic parameters off and on LT4 therapy. Each line between 
two dots represents a patient. P-values represent non-parametric Wilcoxon signed rank test.
Discussion
Although the effects of TH on the cardiovascular system are well-known, the present study 
documented for the first time simultaneously macrocirculation and microcirculation in 
humans in different thyroid states. 
Several well-known consequences of hypothyroidism on the macrocirculation were confirmed, 
including a narrowing of pulse-pressure, decreased heart rate and lower left EDV, left atrial 
volume, CO and SV (5, 6). Together, these changes explain the increase in SVR, concordant with 
early studies (2). The lower early trans mitral inflow (E-top) velocity during hypothyroidism 
is consistent with a reduction of pre-load. Although clinical and subclinical hypothyroidism 
are associated with diastolic dysfunction that can improve upon LT4 replacement therapy, 
we did not observe changes in Doppler-derived diastolic function parameters (5). This might 
be explained by the fact that in our study the duration of the hypothyroid state was relatively 
short compared to other studies (20-22). Indeed, other studies on short-term hypothyroidism 
did not report diastolic dysfunction either (23, 24).
The increase in Tskin-diff and the decrease in PFI represent strong effects on the very peripheral 
circulation upon different thyroid state. Similar findings have been reported previously using 
different techniques (13, 14, 25, 26). Theoretically, there are a few scenarios that potentially 
explain the decreased peripheral circulation in hypothyroidism. First, CO could be insufficient 
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to maintain adequate peripheral perfusion. However, this is less likely as the decrease in CO 
is not as low as typically seen in conditions where decreased CO does affect the peripheral 
circulation (e.g. cardiac forward failure) (11, 27, 28). Furthermore, we did not observe 
correlations between changes in global hemodynamic parameters and changes in Tskin-diff 
or PFI. Second, amelioration of direct effects of TH on the vessel walls in hypothyroidism 
might be an explanation. However, StO2 representing small arteries (hand) and sublingual 
microcirculation are both unaffected. Therefore, a general effect on small blood vessels is 
less likely. Third, the decreased peripheral circulation may be secondary to TH-dependent 
changes in thermoregulation. Given the effects of TH on thermoregulation, cutaneous 
vasoconstriction can be a partial compensation for the reduced central thermogenesis and, 
thus, may have accounted for the decrease in peripheral perfusion in our patients (13, 25, 29). 
The latter possibility would also explain the absence of changes in the sublingual (central) 
microcirculation as this is not involved in (peripheral) thermoregulation.
Our study has certain limitations that need to be taken into account when considering the 
results. First, the number of included patients is small, which is a consequence of the steadily 
growing number of DTC patients that are treated with radioactive iodine after preparation 
with recombinant TSH instead of LT4 withdrawal (30). However, considering the fact that all 
patients were deeply hypothyroid, a clinically relevant effect on the sublingual microcirculation 
should have been detected. Second, although patients reached a deeply hypothyroid state, 
the duration of true hypothyroidism was relatively short. This limits the detection of changes 
that occur during longstanding (subclinical) hypothyroidism. Finally, since all our subjects 
were athyreotic, which can lead to changes in the physiological T3/T4 ratio if levothyroxine 
is supplemented, our results do not necessarily reflect the effect of endogenously produced 
thyroid hormones (31). In addition, several strengths should be mentioned. First, we performed 
a fully integrated assessment of microcirculation and macrocirculation with well-established 
and state-of-the-art tools. Second, the study design included paired analyses, which has the 
advantage to reduce confounders. 
In conclusion, we confirmed several well-known effects of TH on cardiovascular function. In 
addition, we observed that hypothyroidism had profound effects on peripheral perfusion, but 
not on central microcirculation, which is potentially explained as an adaptive mechanism for 
the reduced thermogenesis. Together, our studies reinforce that TH exerts its well-known 
clinical effects on cardiovascular systems through different physiologic mechanisms.
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Abstract
Background: Subjects at risk for major mood disorders have a higher risk to develop 
autoimmune thyroid disease (AITD) and vice-versa, implying a shared pathogenesis. In mood 
disorder patients, an abnormal profile of hematopoietic/neuronal growth factors is observed, 
suggesting that growth/differentiation abnormalities of these cell lineages may predispose 
to mood disorders. The first objective of our study was to investigate whether an aberrant 
profile of these hematopoietic/neuronal growth factors  is also detectable in subjects at risk for 
AITD. A second objective was to study the inter relationship of these factors with previously 
determined and published growth factors/cytokines in the same subjects.
Methods: We studied 64 TPO-Ab-negative females with at least 1 first- or second-degree 
relative with AITD, 32 of whom did and 32 who did not seroconvert to TPO-Ab positivity 
in 5-year follow-up. Subjects were compared with 32 healthy controls (HCs). We measured 
serum levels of brain-derived neurotrophic factor (BDNF), Stem Cell Factor (SCF), Insulin-
like Growth Factor-Binding Protein 2 (IGFBP-2), Epidermal Growth Factor (EGF) and IL-7 
at baseline.
Results: BDNF was significantly lower (8.2 vs 18.9 ng/ml, P<0.001), while EGF (506.9 vs 307.6 
pg/ml, P=0.003) and IGFBP-2 (388.3 vs 188.5 ng/ml, P=0.028) were significantly higher in 
relatives than in HCs. Relatives who seroconverted in the next 5 years had significantly higher 
levels of SCF than non-seroconverters (26.5 vs 16.7 pg/ml, P=0.017). In a cluster analysis with 
the previously published growth factors/cytokines SCF clustered together with IL-1β, IL-6 
and CCL-3, of which high levels also preceded seroconversion. 
Conclusion: Relatives of AITD patients show aberrant serum levels of 4 hematopoietic/
neuronal growth factors similar to the aberrancies found in mood disorder patients, suggesting 
that shared growth and differentiation defects in both the hematopoietic and neuronal system 
may underlie thyroid autoimmunity and mood disorders. A distinct pattern of four inter 
correlating immune factors in the relatives preceded TPO-Ab seroconversion in the next 5 
years.
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Introduction
Autoimmune hypothyroidism is characterized by a combination of clinical features, elevated 
serum TSH with reduced free T4 (FT4) levels, the presence of serum antibodies against thyroid 
antigens, and reduced echogenicity of the thyroid sonogram (1). It is the most common organ-
specific autoimmune disorder with an estimated prevalence of 2%, with a higher prevalence 
in women and depending on iodine intake (2-5). Thyroid peroxidase (TPO) is the major 
autoantigen and TPO antibodies (TPO-Abs) are present in almost all patients with autoimmune 
hypothyroidism (6) and precede the clinical phase of autoimmune hypothyroidism by many 
years. Subclinical autoimmune hypothyroidism (the presence of TPO-Abs with raised TSH 
and normal FT4 levels) is even more prevalent and affects about 9% of the population (2, 
5). In the Whickham follow-up study, women with TPO-Abs had an eight-fold higher risk of 
developing clinically overt hypothyroidism over 20 years than did antibody-negative women 
(7). In our own studies on the Amsterdam AITD cohort (euthyroid females with at least one 
first or second degree relative with a documented autoimmune hyper- or hypothyroidism) 
TPO-Ab positivity at the start of the study also represented a higher risk to develop overt 
hypothyroidism in a follow-up of 5 years (8, 9). In addition, there was a higher conversion rate 
from TPO-Abs negativity to positivity, showing a familial proneness for thyroid autoimmune 
reactivity (9, 10).
In another previous study on this cohort, we tested the hypothesis that serum levels of factors 
related to thyroid growth and connective tissue abnormalities (Platelet-Derived Growth 
Factor (PDGF)-BB, Fibronectin, Metalloproteinase (MMP)-13), to the early accumulation 
of immune cells in the thyroid (soluble Vascular Cell Adhesion Molecule (sVCAM)-1, CCL2, 
CCL4, Angiopoetin-1 Receptor-2 (TIE-2)), and to inflammation (IL-1β, IL-6 and CCL3) were 
related to this proneness for thyroid autoimmunity in the relatives (11). We therefore studied 
these factors in the serum of 64 TPO-Ab negative euthyroid relatives, 32 of whom did and 32 
of whom did not seroconvert to TPO-Abs positivity in 5 year follow-up. The relatives were 
compared with 32 healthy controls. We found that both seroconverting and non-seroconverting 
relatives showed an up regulation of Fibronectin and a down regulation of PDGF-BB, CCL2, 
CCL4, sVCAM-1, TIE-2 and MMP-13. The relatives who later seroconverted (seroconverters, 
SCs) differed from those who did not seroconvert (non-seroconverters, NSCs) by a significant 
up regulation of pro-inflammatory compounds, such as IL-1β, IL-6 and CCL3. We concluded 
that euthyroid females within AITD families show a characteristic pattern of abnormalities in 
serum levels of growth factors, chemokines, adhesion molecules and cytokines, suggesting an 
already compromised thyroid-immune system interaction in the euthyroid family members. 
Also, pre-seroconversion stages might be predicted using serum analytes pointing to a higher 
inflammatory state.
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Autoimmune hypothyroidism is commonly accompanied by depressive symptoms. A 
large epidemiological Danish nationwide, prospective cohort study showed that various 
autoimmune diseases including AITD, are associated with subsequent lifetime mood disorder 
diagnosis (e.g. bipolar affective disorder, unipolar depression, psychotic depression and other 
remaining mood disorders) (12). In hypothyroid patients the lack of thyroid hormone in the 
brain is likely an important determinant for these mood disturbances (13). However, a deficit 
of thyroid hormone may not be the only cause, as even subjects with TPO-Abs with normal 
thyroid function have a higher risk to develop anxiety disorders and mood disorders  (14). 
Also offspring of patients with a bipolar affective disorder have a higher prevalence of TPO-
Abs, even if they are not affected by the psychiatric disorder (15, 16). In addition, a higher 
prevalence of TPO Abs and autoimmune hypothyroidism has been reported in patients with 
bipolar affective disorder, irrespective of the usage of lithium (17, 18). Taken together, these 
associations might imply a shared immune pathogenesis for both AITD and mood disorders. 
We therefore additionally determined, in the sera used in the previous study, 5 growth and 
differentiation factors that have repeatedly been shown to be abnormally expressed in the 
circulation of mood disorder patients and that are capable of influencing both immune and/or 
neuronal cell growth, i.e. SCF, IGFBP-2, EGF, BDNF and IL-7 (19-23). In addition we studied 
the inter relationship of these factors with the previously determined factors using a cluster 
analysis to study patterns of TPO-Ab seroconversion (11). 
Subjects and methods
Subjects 
The Amsterdam AITD cohort has previously been described in detail (8). In the present study, 
we studied serum levels of several hematopoietic/neuronal growth factors in the subjects. In 
addition we assessed the association with TPO-Ab seroconversion like we previously did in the 
study of Beumer et al (11). Therefore, 32 euthyroid subjects were selected who were TPO-Ab 
and Tg-Ab negative at baseline but developed TPO-Abs during follow-up without developing 
an abnormal TSH. Each selected SC was matched with an euthyroid subject who was TPO-Ab 
and Tg-Ab negative at baseline and did not develop TPO-Abs (non-seroconverter) up to the 
time at which the SC to whom they were matched had received her endpoint. SCs and NSCs 
were matched for age, current smoking, current estrogen use, and duration of follow-up. 
As a control group, we selected 32 female subjects from an ongoing program for delineating 
reference values of endocrine function tests that were in self-proclaimed good health, were not 
using chronic medication (except for oral contraceptives), had no family or personal history of 
thyroid disease, and had normal TSH and no thyroid antibodies. Blood samples were collected 
over the same period of time as those of the Amsterdam AITD cohort and were processed in 
the same manner.
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All subjects gave informed written consent and the Medical Ethics Committee of the Academic 
Medical Center in Amsterdam and the Medical Ethics Committee of Erasmus Medical Center 
in Rotterdam approved the study.
TSH, FT4 and TPO-Ab determinations
Serum samples were stored at −20°C until determination of the study parameters. Serum TSH 
and FT4 were measured using time-resolved fluoroimmunoassay (Delphia, Turku, Finland). 
Reference values are 0.4–5.7 mU/L for TSH and 9.3–20.1 pmol/L for FT4. TPO-Abs and Tg-
Abs were measured by chemiluminescence immunoassays (LUMI test anti-TPO and LUMI 
test anti-thyroglobulin, respectively; Brahms, Berlin, Germany). Improved versions of both 
assays became available during follow-up: the detection limits of these new assays were 30 
kU/L for TPO-Abs and 20 kU/L for Tg-Abs. The TPO-Ab concentrations obtained with the old 
assay were multiplied by a factor 0.72 to obtain comparative values in the new assay. TPO-Ab 
and Tg-Ab concentrations were considered to be positive at values greater than 100 kU/L. 
Serum growth factors
We studied a panel of five growth factors at baseline: SCF, IGFBP-2, EGF, BDNF and IL-
7. Serum concentrations were measured using the bead-based Luminex system. These 
multiplexed sandwich immunoassays were developed from commercially available capture 
and detection antibodies (R&D systems) and standard proteins, validated and approved at 
Myriad-EDI-GmbH (Reutlingen, Germany) according to methods described previously (24). 
Subject and healthy control samples were run singular. Assays were measured on either the 
Luminex FlexMap-3D or Luminex 200 system. Results are expressed as picograms per ml or 
nanograms per ml.
EGF, IL-7, SCF, BDNF were measureable in all samples. For IGFBP-2 6.6% of the values 
were above the detection limit. Values above the detection limit were set to the highest value 
observed (IGFBP-2: 19666.5 ng/ml). 
Statistics
Test assumptions were checked by plotting of the data and depending on the distribution 
pattern, parametric (Student’s T-test) or nonparametric group comparisons (Mann-Whitney 
U test) were used for unadjusted group comparisons. All analyses comparing HC, SC and NSC 
groups were subsequently adjusted, for which we used ANOVA. We adjusted for smoking, the 
usage of oral contraceptives, age, BMI and FT4 levels. Because SCs and NSCs were matched 
for age, smoking and estrogen use we did not adjust for these factors when comparing SCs and 
NSCs. If necessary we transformed dependent variables by the natural logarithm. In order to 
improve the interpretability of the group estimates, data are expressed as median with 95% 
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confidence intervals which were calculated using a bootstrap procedure with 1000 draws. For 
IGFBP-2, residuals of the regression analyses remained non-normal after transformation due 
to outliers (n=8), however, we can reliably report the outcomes of the regression analyses as 
these were in line with unadjusted non-parametric results and also remained similar after 
exclusions of the outliers. 
In addition a dendrogram was constructed by SPSS using hierarchical cluster analysis of 
the serum analytes using the between-groups linkage method. For this analysis, we selected 
analytes from the previous study that were significantly different between healthy controls 
and subjects or between NSCs and SCs (S1 Table) and were part of a cluster in that study, and 
combined them with the levels of growth and differentiation factors assessed in the current 
study (11). The associations between TSH, FT4 and the serum growth factors were analyzed 
by linear regression analyses. Level of significance was set at P<0.05 (2 tailed). Statistical 
analysis was performed using SPSS Statistics for Windows, version 21 (IBM Corp., Armonk, 
NY, USA). 
Results
As a result of the matching procedure, SCs and NSCs were not different regarding age, 
current smoking behavior, Body Mass Index (BMI), current estrogen use and TSH or FT4 
levels (Table 1). None of the subjects were using chronic medication. TSH levels were not 
associated with any of the growth and differentiation factors (data not shown). FT4 levels 
were positively associated with IGFBP-2 levels (β±SE 0.16 ±0.075; P=0.037) and we observed 
a non-significant trend with SCF (β±SE 1.2 ±0.68; P=0.069). FT4 was not associated with the 
other growth factors. 
Table 1. Baseline characteristics
P-values
Controls SC NSC SC vs C
NSC  
vs  C
NSC 
vs SC
Number of subjects 30 30 31
Age, mean (range) 35.2 (21-61) 33.3 (18-61) 33.5 (19-62) 0.5 0.56 0.93
BMI, mean (range) 22.7 (18-33) 24.1 (19-41) 24.2 (19-42) 0.22 0.17 0.95
Current smoking, % 12 (40%) 14 (46%) 14 (45%) 0.61 0.69 0.9
Current estrogen use, % 5 (17%) 11 (37%) 12 (38%) 0.055 0.083 0.87
TSH median (95% CI) 1.3 (1.1-1.7) 1.4 (1.3-1.7) 1.2 (1-1.5) 0.36 0.66 0.13
FT4 median (95% CI) 13.2 (12.9-14.6) 12.8 (12.4-13.5) 13.7 (13-14.2) 0.53 0.60 0.25
Characteristics of healthy controls (C) and relatives of AITD patients grouped for TPO antibody conversion during 
follow-up (seroconverters (SC) and non seroconverters (NSC)). Due to a lack of serum, the total number of subjects per 
group is not equal to the original 32.
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Subjects versus healthy controls
Table 2 shows the median levels of the 5 tested growth and differentiation factors in the 
healthy controls and in the subjects. IGFBP-2 levels were significantly higher in the relatives 
than in the healthy controls (P=0.028). Serum levels of EGF were also significantly higher in 
the relatives than in the healthy controls (P=0.003). Serum levels of BDNF were significantly 
lower in the relatives than in the healthy controls (P<0.001). Serum levels of SCF and IL-7 
were not statistically different between relatives and healthy controls. 
Table 2. Comparison of growth and differentiation factors between healthy controls and subjects
Controls Subjects P-value Adjusted P-value
EGF (pg/ml) 307.6 (110-409) 506.9 (428-612) 0.001 0.003
BDNF (ng/ml) 18.9 (14.6-22.7) 8.2 (7.3-9.3) <0.001 <0.001
IGFBP-2 (ng/ml) 177.8 (142- 235) 252.5 (177-351) 0.073 0.028
SCF (pg/ml) 22.6 (17.4-26.4) 22.6 (16.7-27.1) 0.58 0.70
IL-7 (pg/ml) 4.0 (2.8-5.1) 3.7 (3.0-3.8) 0.18 0.26
Median levels (95% CI) of EGF, BDNF, IGFBP-2, SCF and IL-7 in healthy controls and in subjects overall. Adjusted 
P-values are adjusted for age, BMI, smoking, oral contraceptive usage and FT4 levels.
Table 3. Serum levels of growth and differentiation factors in healthy controls (C), Seroconverting (SC) 
and Non-Seroconverting (NSC) family members.
Adjusted P-values
Controls SC NSC SC  vs C
NSC 
vs C
SC  
vs NSC
EGF (pg/ml) 307.6 (110-409) 564.2 (411-803) 470.6 (355-612) 0.017 0.011 0.79
BDNF (ng/ml) 18.9 (14.6-22.7) 8.7 (5.1-10.8) 8.1(6.9-9.3) <0.001 <0.001 0.45
IGFBP-2 (ng/ml) 177.8 (142- 235) 233.2 (153-376) 252.5 (164-390) 0.16 0.019 0.31
SCF (pg/ml) 22.6 (17.4-26.4) 26.5 (22.5-31.9) 16.7 (12.3-22.8) 0.49 0.26 0.017
IL-7 (pg/ml) 4.0 (2.8-5.1) 3.4 (2.7-3.8) 3.7 (3.0-4.0) 0.076 0.55 0.25
Median levels (95% CI) of EGF, BDNF, IGFBP-2, SCF and IL-7. 
Seroconverters versus non-seroconverters
Table 3 shows that SC subjects had significantly higher levels of SCF than NSC subjects 
(P=0.017). Serum levels of SCF were not statistically different between SCs and healthy 
controls and between NSCs and healthy controls (P=0.49 and P=0.26, respectively). The 
serum levels of IGFBP-2, EGF, BDNF and IL-7 were not significantly different between SCs 
and NSCs. Serum levels of EGF were significantly higher in SCs and in NSCs than in healthy 
controls (P=0.017 and P=0.011, respectively). Serum levels of BDNF were significantly lower 
in SCs and in NSCs than in healthy controls (P<0.001 in both groups). A non-significant trend 
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towards lower levels of IL-7 in the SCs than in controls was observed (P=0.076). IGFBP-2 
levels were higher in both groups of subjects than in healthy controls which was significant in 
the NSCs (P=0.019).
Cluster analysis   
Taking the analytes which we have previously determined also into account we found in the 
cluster analysis two mutually correlating clusters of analytes: one stronger inter correlating 
cluster A and a weaker inter correlating cluster B (Figure 1) (11). Cluster A contained the 
inflammatory cytokines/chemokines IL-1β, CCL3 and IL-6, the connective tissue modulator 
MMP-13 and the hematopoietic/neuronal growth and differentiation factor SCF, while cluster 
B contained the pro-inflammatory chemokines CCL2 and CCL4, the endothelial adhesion 
molecule sVCAM-1, PDGF-BB, and the T cell and NK cell growth factor IL-7. The heat map 
shows that the growth factors IGFBP-2, EGF and BDNF barely correlated to each other and 
to the other analytes. 
Table 4.  Patterns of expression levels of cytokines, chemokines and growth and differentiation factors, 
assessed in the previous study of Beumer et al. and in the current study [7].
NSC vs HC SC vs NSC SC vs HC
Pattern 1
Fibronectin (µg/ml)
IGFBP-2 (ng/ml)  
EGF (pg/ml)
Pattern 2
CCL4 (pg/ml) 
MMP-13 (ng/ml) 
CCL2 (pg/ml) 
sVCAM-1 (µg/ml) 
PDGF-BB (pg/ml)
BDNF (ng/ml)
Pattern 3
IL-1β (pg/ml) 
IL-6 (pg/ml) 
CCL3 (pg/ml) 
SCF (pg/ml)
Other
IL-7 (pg/ml)
Patterns of expression levels in serum compounds between seroconverters (SC) and non-seroconverters (NSC) and 
healthy controls (HC).  and  indicates significantly higher or lower serum levels respectively, and  indicates that 
serum levels are not significantly different (S1 table).
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Regarding the pattern of expression in the two study groups (SCs and NSCs) three patterns of 
reactivity could be detected (S1 Table and Table 4). There were factors, which were higher in 
the serum of both SCs and NSCs than in controls, such as the growth factors IGFBP-2, EGF 
and the repair factor Fibronectin. There were also factors that were lower in the serum of both 
SCs and NSCs than in controls, such as CCL4, CCL2, sVCAM-1, BDNF and PDGF-BB. Finally, 
there were factors that were higher in the SCs than in the NSCs such as IL1-β, IL-6, CCL3 and 
SCF (Supplemental Table 1 and Table 4).  
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Figure 1. Cluster analysis. Heat map of hierarchical cluster analysis of the  serum levels of cytokines, 
chemokines, growth factors and tissue remodeling factors in the relatives. Color-coded correlation matrix 
illustrates Pearson’s correlation coefficients.  Significant positive correlations are given in the red scale 
(darkest red are correlation coefficients > 0.50), and significant negative correlations are given in the 
(dark) green scale.  Lighter fields are not significant. In addition, a dendrogram is presented as a result of 
the hierarchical clustering. A indicates cluster A and B indicates cluster B.  
Discussion
The present study shows that euthyroid females, who are relatives of AITD patients and at risk 
of developing AITD, have an aberrant serum level of 4 of the 5 tested hematopoietic/neuronal 
growth and differentiation factors, i.e. of BDNF, IGFBP-2, EGF and SCF. BDNF levels were 
significantly lower and  IGFBP-2 and EGF higher expressed in sera of the relatives of the AITD 
patients (in both SCs and NSCs) than in healthy controls. IL-7 levels were normal. We also 
found in the healthy relatives, who converted in the following 5 years to TPO-Ab positivity, 
significantly higher serum levels of SCF than in relatives who did not. 
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It is of note that the 5 studied factors have been highlighted as serum biomarkers for major 
mood disorders in several studies (19-23) and are involved in neurogenesis, neuroprotection 
and hematopoietic differentiation (25-29). This is in particular known for BDNF. Neurotrophic 
factors, like BDNF, play an important role in neuronal plasticity, modulating not only 
axonal and dendritic growth and remodeling, but also neurotransmitter release and synapse 
formation (30, 31). Neuronal plasticity is a complex process which is illustrated by the complex 
interaction between the neurotrophic factors and its receptors. The cellular actions of BDNF, 
for example, are mediated through TrkB (tyrosine kinase receptor) and by p75 neurotrophin 
receptor (p75NTR) (32). Binding of dimeric BDNF causes dimerization of TrkB receptor 
and autophosphorylation of intracellular tyrosine residues. Activation of TrkB receptor 
leads to signaling cascades involving activation of Ras/ERK pathway, phosphatidylinositol 
3-kinase (PI3K) and Phospholipase Cγ (33). The Ras pathway regulates neuronal survival 
and differentiation through downstream signaling that includes c-RAF/B-Raf/ERK1/ERK2. 
Brunoni et al. showed in a meta-analysis that BDNF levels were decreased in patients with a 
major depressive disorder and were also associated with clinical changes in depression (34). 
This study also extends our previous study and shows that the here reported 5 growth factors 
and the previously reported 9 growth factor/cytokines form three patterns of reactivity in 
the relatives of AITD patients when compared to healthy subjects and depending on TPO-
Ab seroconversion within the next 5 years (11). This study and the previous one therefore 
underscore the widespread changes in immune-neuro-endocrine molecular networks that 
apparently precede the appearance of TPO-Abs, which opens avenues for developing assays 
for the detection of individuals at risk for thyroid autoimmunity.
Combining this study with the previous one we found factors which were raised in the 
relatives, irrespective of later seroconversion, such as the growth factors IGFBP-2, EGF and 
the repair factor Fibronectin. None of these factors inter correlated. There were also factors 
that were reduced in the serum of the relatives irrespective of later seroconversion, such as the 
chemokines CCL4, CCL2, the adhesion molecule sVCAM-1, and the growth factors BDNF and 
PDGF-BB. Many of these factors inter correlated in cluster B in the dendrogram constructed 
in this article. Taken these two patterns of reactivity together, the serum aberrancies suggest 
another state of growth regulation of multiple cell lines (including neuronal and hematopoietic 
cells) and another state of leukocyte migration in relatives of AITD patients. 
Finally, there were factors that were higher in the SCs than in the NSCs such as IL1-β, IL-6, 
CCL3 and SCF, while often being lower in the NSCs than in controls. These factors correlated 
to each other in cluster A in the dendrogram. We assume that the generally low expression in 
NSCs in cluster A reflects an immune suppressive state preventing autoimmunity, while a rise 
of these pro-inflammatory compounds precedes a conversion to TPO-Ab positivity and thus 
may reflect a very early stage of thyroid auto reactivity. In recent studies, the importance of T 
helper 1 lymphocytes in the induction of such auto-inflammatory state has been shown (35). A 
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further investigation of cytokines and chemokines reflecting the higher state of the T helper 1 
system (such as IL-12, IFN-γ and CXCL-10) in relatives of AITD index cases deserves further 
attention (36, 37). 
A limitation of our study is the relatively small sample size. Also, because this is an explorative 
study which focused on 5 non-random selected analytes, we did neither take type I errors into 
account nor applied a correction for multiple testing. Our study is also limited by the fact that 
we did not assess the association between the levels of these growth and differentiation factors 
and the mood state of the relatives (sampling of the sera occurred 15 years ago, at the time 
we were unaware of the link between AITD and depression). Next, we used a BDNF antibody 
in our immunoassay, which was developed to measure mature BDNF. It is now known that 
there are other assays and antibodies on the market that also measure pro-BDNF (38). It has 
been reported, however, that in particular mature BDNF is important in major depression 
(39) although this needs exploration. Furthermore, also other factors important in neuronal 
growth and differentiation should be taken into account, such as glial-cell-line-derived 
neurotrophic factor (GDNF). GDNF signals through a multicomponent receptor complex 
comprising the Ret proto-oncogene (RET) tyrosine kinase and the GDNF family receptor 
(GFR)α (40). Following GDNF binding in the presence of co-receptor GFRα, RET becomes 
dimerized and tyrosine phosphorylated and triggers different pathways (Ras-MAPK, PI3K-
Akt). Finally, in the paragraph above, we have highlighted that other immune factors which 
are linked to the induction of thyroid autoimmunity (such as T helper 1 related factors) should 
be explored. It is also evident that our studies need confirmation and expansion in larger 
families and follow-up studies, taking many more neuronal, endocrine and immune factors 
into consideration to unravel the changes in immune-neuro-endocrine molecular networks 
that precede and probably underlie the development of AITD and mood disorders. 
Since a large number of autoimmune hypothyroid patients have a diminished cognitive and 
psychological function despite adequate levothyroxine replacement therapy, another next 
step could be to measure the growth and differentiation factors in these patients and to assess 
the association with these symptoms.
We conclude that subjects at risk for AITD show changes in growth and differentiation factors 
in serum, which are both active as neuronal and hematopoietic growth and differentiation 
factors and are abnormally expressed in patients with mood disorders. This suggests that 
shared growth and differentiation defects in both the hematopoietic and neuronal system may 
underlie both thyroid autoimmunity and mood disorders. 
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Abstract
Background: Levothyroxine (LT4) is the standard of care in patients with hypothyroidism. 
Despite this replacement therapy, quality of life (QoL) remains impaired in a substantial 
amount of patients. The reasons for this are still a matter of debate. Suggested causes include 
lack of endogenous T3 secretion by the thyroid, changes in other thyroid hormone metabolites, 
and interference by autoimmune processes. 
Objective: To investigate the association between thyroid function tests (TFTs) and QoL 
in patients with a history of differentiated thyroid cancer on LT4 monotherapy. These 
patients lack endogenous thyroidal T3 secretion in the absence of autoimmune disease. 
Materials and Methods: This is a cross-sectional study in 143 patients (69.2% female). Initial 
therapy consisted of total thyroidectomy followed by radioiodine ablation minimally one year 
before inclusion. We assessed health-related QoL (RAND-36), thyroid specific QoL (ThyPRO) 
and fatigue with the Multidimensional Fatigue Inventory. Extensive TFTs were assessed, 
including 3,5-diiodo-L-thyronine (3,5-T2). 
 
Results: Mean age was 50.2 years and mean time since diagnosis was 8.4 years. Median 
TSH was 0.042 mU/l, total T4 145.0 nmol/l, free T4 25.6 pmol/l, total T3 1.93 nmol/l, reverse 
T3 0.53 nmol/l, and 3,5-T2 0.86 nmol/l. Multiple linear regression analyses did not show 
any association between QoL and the different TFTs, including T4/T3 and 3,5-T2/T3 ratios 
reflecting peripheral metabolism. 
 
Conclusion: We did not find any association between TFTs and QoL in athyreotic patients 
on LT4 monotherapy. Our data do not provide evidence that a slight increase in dose improves 
fatigue or  well-being in hypothyroid patients on LT4 therapy. 
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Introduction
Hypothyroidism is one of the most common endocrine disorders(1). Despite adequate 
restoration of biochemical euthyroidism with replacement therapy with levothyroxine (LT4), 
a substantial part of patients (~10-15%) display significant impairment of psychological well-
being compared to controls of similar age and sex and show decrements in health status (2-
6). There are a couple of explanations for these persisting symptoms. First, the presence of 
associated autoimmune diseases or thyroid autoimmunity per se could account for persisting 
symptoms (7-9). However, cured patients with differentiated thyroid carcinoma (DTC) on 
LT4 replacement therapy have also been shown to have an impaired quality of life  (QoL)
(10),(11). Second, it might be the inadequacy of LT4 treatment to restore physiological T4 
and T3 concentrations in serum and tissues (12, 13). Approximately 15% of circulating T3 
in euthyroid patients is secreted by their thyroid gland. Nevertheless, in patients with 
hypothyroidism, LT4 monotherapy is the standard of care. The peripheral conversion of LT4 
to T3 makes it possible to achieve normal T3 concentrations in patients treated with LT4, 
albeit with the necessity for maintaining T4 concentrations at the higher end of the normal 
range (14-16). Studies in hypothyroid rats showed that LT4 monotherapy was not able to 
normalize concentrations of T4 and T3 in all tissues (17). The LT4 dose needed to normalize 
thyroid hormone concentrations was different for each tissue, and supra- physiological serum 
T4 concentrations had to be reached in most tissues to normalize their T3 concentrations. 
However, addition of synthetic T3 to LT4 treatment regimens is controversial. Although two 
studies found benefits of adding T3 therapy (18),(19), most studies did not (16, 20). A meta-
analysis of 11 studies that had been performed so far comparing the effectiveness of T4-T3 
combination therapy vs LT4 monotherapy, did not find any improvement of symptoms and 
QoL for T4-T3 combination therapy (21). 
Studies investigating the relationship between TFTs and QoL have not produced unequivocal 
results. Importantly, most studies were performed in patients with autoimmune thyroid 
disease (AITD) in which autoimmunity might have affected QoL (2, 3, 6). Anecdotal evidence 
suggests that some patients with hypothyroidism benefit from titrating the LT4 dosage until 
serum TSH is in the lower part of the reference range although this was not confirmed by the 
only clinical trial investigating this approach (22). 
Furthermore, it remains unknown whether other endogenous thyroid hormone metabolites 
with T3-agonistic or antagonistic activities, like 3,5-diiodo-L-thyronine (3,5-T2), might play 
a role in the persisting symptoms and decreased QoL among hypothyroid patients. Recent 
studies have shown that 3,5-T2 concentrations are higher in thyroidectomized patients on LT4 
substitution therapy as compared with healthy controls, suggesting extrathyroidal production 
or conversion (23). The metabolic pathways or enzymes involved in this reaction in vivo have 
not been characterized, yet growing evidence shows that 3,5-T2 plays an important role in 
energy metabolism (24), (25). The association between 3,5-T2 and QoL amongst hypothyroid 
patients has never been investigated. 
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In this cross-sectional study we therefore measured classical TFTs and assessed concentrations 
of 3,5-T2 with a recently developed competitive chemiluminescence immunoassay (23). We 
subsequently investigated whether thyroid hormones or their metabolites were associated 
with various QoL outcomes in patients with a history of DTC, lacking functional thyroid tissue 
but who were not affected by AITD. 
Patients and Methods
DTC patients, 18-80 yrs. old, were consecutively recruited from the outpatient clinic of the 
Erasmus Medical Center, between November 1st 2013, and December 31st 2014. Initial therapy 
consisted of total thyroidectomy, followed by ablation therapy with I-131 (except for the 
patients with medullary thyroid carcinoma; N=7). Patients were eligible for inclusion in the 
study if either cured from DTC and initial therapy was finished at least one year before study 
inclusion or if they had stable disease; TSH concentrations were lower than 4.3 mU/l and no 
changes were made in the LT4 dosage during the past 10 weeks (to ensure that all patients 
were adequately treated with LT4  monotherapy in a stable dosage); patients were able to 
comprehend and complete the Dutch questionnaires; and had negative titers for thyroglobulin 
antibodies (Tg-Abs< 40 IU/ml). Patients with other malignancies or an active inflammatory 
disease were excluded.  
In total 263 patients were screened for eligibility. Out of the 159 patients meeting the inclusion 
criteria, 5 patients refused participation. Of the 154 enrolled patients, 11 did not complete the 
questionnaire.
Cure after initial therapy was defined as: a negative whole body iodine 131 post-therapy scan, 
a Tg concentration less than 0.9 µg/l on LT4 therapy in absence of Tg-Abs (<10  IU/ml), 
or a calcitonin concentration of less than 2 ng/l for patients with MTC, an undetectable Tg 
concentration after stimulation with recombinant TSH, and no signs of tumor remnant/ 
recurrence on the ultrasound of the neck. 
The study protocol was approved by the Medical Ethics Committee of the Erasmus Medical 
Center and written informed consent was obtained from all study participants.
Quality of life questionnaires
Thyroid-specific patient reported outcome measure (ThyPRO)
The ThyPRO is a thyroid-specific QoL questionnaire which consists of 85 questions 
summarized in 13 scales. It detects clinically relevant differences among thyroid patients and 
has good cross-cultural validity 25,(26). Scores vary from 0-100 with higher scores indicating 
more thyroid-related complaints. Since the Goiter symptoms scale, the Eye symptoms scale, 
and the Cosmetic complaints scale are not relevant in patients with treated thyroid carcinoma, 
these three scales were not analyzed. 
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Multidimensional fatigue index-20 (MFI-20)
The MFI is a 20-item self-report instrument designed to assess fatigue. Scores vary from 0 to 
20 with higher scores indicating greater fatigue. It covers the following dimensions: General 
Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity (27). 
RAND-36-item health survey (RAND-36)
The RAND-36 is the validated Dutch version of the SF-36. It is a generic questionnaire which 
determines the overall health-related QoL during the previous 30 days (28). It consists of 9 
subscales: physical functioning, social functioning, role limitations because of physical health 
problems, role limitations because of emotional health, general mental health, vitality, bodily 
pain, general health perception and general health change. Scores are expressed on a 0-100 
scale, and higher scores are associated with a better QoL. Two well-known summary scores 
of the subscales were computed: the mental component score and the physical component 
score (29). The scores on the RAND-36 subscales were compared with an age-matched Dutch 
reference group(28). Reference values were computed from a random sample of 1063 persons 
(65% females) from the register of the city of Emmen. 
Thyroid function measurements
Peripheral blood samples were obtained from all participants. Serum Free T4 (FT4, reference 
range 11-25 pmol/l), total T4 (TT4, reference range 58-128 nmol/l) and total T3 (TT3, reference 
range 1.4-2.5 nmol/l) concentrations were measured by chemoluminescence assays (Vitros ECI 
Immunodiagnostic System; Ortho-Clinical Diagnostics, Rochester, MI). Serum TSH (reference 
range 0.4-4.3 mU/l) was determined by immunometric assay (Immulite 2000 XPi, Siemens, 
Den Haag, the Netherlands) and rT3 concentrations (reference range 0.22-0.54 nmol/l) were 
analyzed by  radioimmunoassay (ZenTech, Angleur, Belgium). Serum 3,5-T2 concentrations 
were quantified with a recently developed monoclonal antibody-based chemiluminescence 
immunoassay in the laboratory of the Institute of Experimental Endocrinology, Charité-
Universitätsmedizin Berlin in Germany (23). In 761 euthyroid participants of the population-
based Study of Health in Pomerania  median 3,5-T2 concentrations were 0.24 nmol/l (1st 
quartile: 0.20 nmol/l; 3rd quartile: 0.37 nmol/l) (30).  
Statistical analysis
The association between TFTs and patient characteristics was analyzed by linear regression 
analyses. Nonlinearity was assessed using restricted cubic splines analyses, or sensitivity 
analyses focusing on variations in R-squared values in which independent variables were 
added to the model with quadratic or cubic terms and multiple linear regression models were 
built accordingly. TSH, 3,5-T2, TT3, TT4 and rT3 showed non-normally distributed  residuals 
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and were logarithmically transformed to normalize the skewed distribution. The association 
between QoL and TFTs was analyzed by linear regression analyses as well. All analyses were 
adjusted for age, sex, body mass index (BMI), the number of years since diagnosis, the number 
of drugs used and being cured or not. The number of drugs was used as a proxy variable for 
general health and/or comorbidities. The mental component scores, the physical component 
scores, some of the RAND-36 subscales and the MFI scales showed non-normal distribution 
of the residuals and had to be normalized using a Tukey transformation. As transformation 
did not normalize the residuals of ThyPRO scales, we used a logistic regression analyses 
investigating the risk of being in the highest tertile for symptom score. In addition, we also 
investigated the association between TFTs and ThyPRO scales by ordinal logistic regression 
(with tertiles of the symptom scores) and standard linear regression which all yielded similar 
results (data not shown). The health-related QoL (RAND-36) scores were compared with a 
Dutch reference group using the non-parametric 
one sample sign test. In order to cope with the large number of statistical tests within our study 
population we used the Benjamini-Hochberg false discovery rate controlling procedure and 
we allowed for a maximum of one result of all non-overlapping tests (i.e. not counting ratios 
and not counting multiple fatigue measurements) to be false positive; this corresponded with 
a cut-off of  P< 0.012 for statistical significance. Statistical analysis was performed using SPSS 
Statistics for Windows, version 21 (IBM Corp., Armonk, NY, USA) and R statistical software 
v.3.03 using the rms and fdrtool package. 
Results
Characteristics of the study patients are shown in Table 1. We analyzed 143 patients with a 
mean age of 50.2 years of whom the vast majority (82.6%) was diagnosed with a papillary 
thyroid carcinoma. All patients had undergone a total thyroidectomy. A lymph node dissection 
was performed in 35 % of the patients, mostly a combined central and ipsilateral procedure. 
Eighty percent of patients were cured and the others had stable disease.
TFTs
At the time of the survey, median TSH concentrations were 0.042 mU/l (Inter Quartile Range 
0.007-0.21), median TT4 concentrations were 145.0 nmol/l (128.0-170.0), median FT4 
concentrations were 25.6 pmol/l (23.0-29.0), median rT3 concentrations were 0.53 nmol/l 
(0.45-0.65), while median TT3 concentrations were 1.91 nmol/l (1.74-2.10) (Table 1). Median 
3,5-T2 concentrations were 0.86 nmol/l (0.55-1.17), which is higher than the median 3,5-T2 
concentrations assessed in serum from thyroidectomized and LT4-substituted patients (0.48 
± SD 0.03 nmol/l, n=100) by Lehmphul et al.(23).
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Table 1. Characteristics of study participants
Male
Female
44 (30.8)
99 (69.2)
Age, mean ±SD (range), years 50.2 ± 13.3 (19.4-78.4)
BMI, mean ±SD, kg/m2 27.9 ± 5.6
Time since diagnosis, mean ±SD, years 8.4 ± 7.8
Dose LT4, mean ±SD, µg 180.9 ± 55.0
Dose LT4 per kg, mean ±SD, µg/ kg 2.18 ± 0.54
Number of drugs, mean ±SD (range) 2.8 ± 2.3 (1-11)
Diagnosis N (%)
   PTC
   FTC
   MTC
Cured 
118 (82.5) 
18 (12.6)
7 (4.9)
114 (79.7)
Surgery N (%)
   Total thyroidectomy 
   Total thyroidectomy + neck dissection 
93 (65)
50 (35)
Postoperative hypoparathyroidism N (%) 20 (14)
Number of I-131 therapies N (%)
   0   (MTC)
   1
   2
   3
   4
   5
   7
   Unknown
7 (4.9)
71 (49.7)
30 (21.0)
22 (15.4)
7 (4.9)
2 (1.4)
1 (0.7)
3 (2.1)
TSH, median (reference range), mU/l 0.042 (0.4-4.3)
FT4, median (reference range), pmol/l 25.6 (11.0-25.0)
TT4, median (reference range), nmol/l 145.0 (58.0-128.0)
TT3, median (reference range), nmol/l 1.93 (1.4-2.5)
rT3, median (reference range), nmol/l 0.53 (0.22-0.54)
3,5-T2, median (IQR), nmol/l 0.86 (0.55-1.17)
The dosage of LT4 per kilogram was positively associated with FT4 and TT4 concentrations 
(P= 0.003 and P= 0.004 respectively) while there was a trend towards a negative association 
with TSH concentrations (P= 0.017). In contrast, TT3, rT3 and 3,5-T2 concentrations were not 
associated with the dosage of LT4 per kilogram (Table 2). In this cohort, 3,5-T2 concentrations 
showed a trend towards a positive association with age (P= 0.04), but no association was 
noted for BMI or sex of the subjects. TT4 concentrations tended to be lower in males (P= 
0.017) and TT4 concentrations were positively associated with BMI of the subjects (P< 0.001). 
FT4 concentrations were associated with TSH, TT3 and rT3 concentrations but not with 3,5-
T2 concentrations (Figure 1).
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Figure 1. The association between FT4 and TSH, TT3, rT3 and 3,5-T2.
Analysis were adjusted for BMI, age and sex of the subjects.
Table 3. Comparison of RAND-36 scores with the Dutch population.
RAND-36 Subscales Study Patients Reference Scores P
Physical functioning 85.0 (70.0-95.0) 79.9 (72.7-90.0) 0.35
Social functioning 75.0 (62.5-100.0) 86.4 (86.1-88.0) <0.001
Role limitations; physical 68.75 (50.0-93.8) 78.9 (76.5-82.9) <0.001
Role limitations; emotional 75.0 (58.3-100.0) 83.6 (82.2-86.8) <0.001
General mental health 65.0 (55.0-80.0) 76.9 (76.7-77.1) <0.001
Vitality 50.0 (37.5-62.5) 67.1 (67.0-67.5) <0.001
Bodily pain 100.0 (67.3-100.0) 80.5 (74.7-83.8) 0.008
General health perception 60.0 (40.0-70.0) 71.6 (64.4-74.0) <0.001
General health change 50.0 (50.0-50.0) 51.9 (48.7-55.4) 0.001
RAND-36 scores in study patients compared with age-adjusted reference values from the Dutch population. Data are 
expressed as median (IQR).
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Quality of Life
Table 3 shows that our subjects scored lower on all RAND-36 subscales compared with a 
Dutch reference group, except for the subscales physical functioning and bodily pain. Table 4 
and Supplemental Table 1 show the association of TFTs with the mental component score and 
the physical component score of the RAND-36, and the ThyPRO scales. None of the TFTs was 
associated with QoL outcomes in our subjects. As for other determinants of QoL, the number 
of drugs used by the patient showed a negative association that was consistent for both of 
the RAND summary scales (P< 0.001 and P= 0.001). Also, time since diagnosis consistently 
showed a trend towards a positive association with both summary scales of the RAND-36 (P= 
0.038 and P= 0.012). Curation, BMI and hypoparathyroidism (data not shown) were neither 
associated with RAND summary scales nor with ThyPRO scales. 
Supplemental Table 2 shows that there is no association between TFTs and the MFI 
dimensions. The number of drugs used by the patient was positively associated with fatigue 
in four of the five subscales of the MFI. However, after correction for multiple testing this 
association was no longer significant except for the dimension physical fatigue (P= 0.006). 
Discussion 
In this cross-sectional study among athyreotic patients with a history of DTC, there was no 
consistent association of TFTs with health-related QoL. Since all our patients lack functional 
thyroid tissue due to surgery and radioiodine ablation therapy, and none of the patients had 
evidence for AITD, we were able to study the isolated effects of LT4 monotherapy in a very 
homogenous group. 
Our patients were treated with relatively high dosages of LT4 leading to high but not thyrotoxic 
TT4 and FT4 concentrations while their total TT3 concentrations remained within the reference 
range. Previous studies already demonstrated a decreased ratio of TT3 to TT4 in patients 
after thyroidectomy receiving LT4 monotherapy (16), (31) ,(15). However, these authors did not 
assess the association with QoL. In the current study, there was no association between TFTs, 
including their ratios, and health-related QoL or thyroid specific QoL. As fatigue is common 
among patients with thyroid disease, we also used the MFI to assess fatigue. However, there 
was no association between TFTs and fatigue either. Subgroup analysis of patients with the 
lowest TT3 concentrations did not show a decreased QoL or increased fatigue either (data 
not shown). This is in line with data from Walsh et al., who reported that small changes in 
LT4 dosage did not lead to changes in hypothyroid symptoms, well-being or QoL (22). Other 
authors could not find an association between QoL and TSH concentrations (10, 32, 33). 
Taken together, these data suggest that there is no relationship between a large set of thyroid 
function parameters and complaints of fatigue or impaired well-being in hypothyroid patients 
on LT4 therapy.  
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We speculated that other T4-derived endogenous thyroid hormone metabolites like 3,5-
T2 might be involved in eliciting persisting complaints and symptoms. Pharmacological 
application of 3,5-T2 in rodent models enhances energy metabolism by increasing lipid 
oxidation and mitochondrial activity, activates brown adipose tissue thermogenesis and 
prevents hepatic steatosis and insulin resistance (25, 34), albeit some of these effects 
remain controversial (35-37). However, little is known about the role of 3,5-T2 in human 
metabolism. Recently, an association between 3,5-T2 concentrations and serum fasting 
glucose concentrations and leptin concentrations was detected in healthy euthyroid humans 
(30), an observation which might be of interest in context of frequent complaints of weight 
gain associated with LT4 replacement therapy after thyroidectomy (38, 39). However, we 
could not find any association between 3,5-T2 concentrations and QoL as well. Of course, we 
cannot rule out that the thyroid gland of healthy individuals produces other thyroid hormone 
metabolites, we are not able to assess yet. Such metabolites might be associated with QoL or 
might directly impact on or be associated with fatigue or other symptoms of discontentedness 
with LT4 therapy. Concentrations of 3,5-T2 were not associated with the dosage of LT4 and 
showed no association with (F)T4 and TT3 concentrations either.     
Health-related QoL was overall lower in our patients compared with a Dutch reference 
group. This might be explained by the fact that our patients had been diagnosed with thyroid 
cancer(10, 11). However, health-related QoL and cancer disease status (being cured or not) 
was not correlated in our patients. Although health-related QoL and years since diagnosis 
showed some relation, this failed to reach significance after correction for multiple testing. 
However, since similar results have been reported for duration of cure in other cohorts of 
DTC patients(10), QoL seems to improve when time since diagnosis increases. A limitation 
of the reference group is that its characteristics are somewhat different. The reference group 
has a slightly lower percentage of females (65% vs. 69% in our cohort), was from another, 
more rural area in The Netherlands and questionnaires were taken in the 90’s. The number 
of drugs used by the patient was negatively associated with QoL in the current cohort, which 
is most likely explained by co-occurrence of co-morbidities. Permanent hypoparathyroidism 
was not associated with QoL. BMI was not associated with QoL, which is in contrast with 
recent findings from Kelderman-Bolk et al., who found an association between QoL and BMI 
in hypothyroid patients, mostly caused by AITD (6). This might be explained by a difference in 
BMI between the two studies, since mean BMI was higher in their study patients than in our 
patients (29.1 kg/m2 vs 27.9 kg/m2, respectively). 
This study is to our knowledge the first study that describes an extensive thyroid hormone 
metabolite profile, including rT3 and 3,5-T2 concentrations, in a population of athyreotic 
patients treated with LT4 in the context of an in depth QoL evaluation. This study has some 
limitations: first of all, the observational and cross-sectional design of the study limits the 
determination of causal inference, and second, we were only powered to statistically detect 
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relatively large effects due to the limited number of included participants and the well-recognized 
measurement error of QoL questionnaires. With regards to the latter, it is important to note 
that our results for QoL were consistent across different questionnaires and their subsets. It is 
therefore unlikely that the association between QoL and TFTs would change with increasing 
study participants. However, the questionnaires we used might have been not sensitive enough 
to detect an association with TFTs. The ThyPRO has been developed to measure the impact 
of any benign thyroid disease on health-related QoL, while our patients have been treated 
(and cured in majority of cases) for DTC. Our patients were treated with supraphysiological 
LT4 doses but were not overtly thyreotoxic, as evident from serum TT3-concentrations in 
the reference range. It is unclear to what extent the ThyPRO is able to assess changes in QoL 
in the euthyroid range/ subclinical range. Finally, we were only able to measure TFTs in 
serum, which might not reflect tissue concentrations as we mentioned in the introduction. 
In conclusion, we did not find any association between TFTs and health-related QoL nor with 
thyroid specific QoL and fatigue in athyreotic patients with a history of DTC. Our data do not 
support the hypothesis that complaints of fatigue and/or impaired well-being in hypothyroid 
patients on LT4 therapy are due to relatively low levels of serum T3 because of a lack of 
endogenous T3 secretion by the thyroid gland or to altered concentrations of T4 metabolites. 
The lack of association between QoL and a detailed set of TFTs in this cohort provides no 
evidence for the hypothesis that slight increments in LT4 and/ or T3 dose would improve 
fatigue or impaired well-being in hypothyroid patients.
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Abstract
Background: Levothyroxine replacement treatment in hypothyroidism is unable to 
restore physiological thyroxine and triiodothyronine concentrations in serum and tissues 
completely. Normal serum thyroid stimulating hormone (TSH) concentrations reflect only 
pituitary euthyroidism and, therefore, novel biomarkers representing tissue-specific thyroid 
state are needed. MicroRNAs (miRNAs), small non-coding regulatory RNAs, exhibit tissue-
specific expression patterns and are detectable in serum. Previous studies have demonstrated 
differential expression of (precursors of) miRNAs in tissues under the influence of thyroid 
hormone. 
Objective: To study if serum miRNA profiles are changed in different thyroid states.
Design and methods: We studied 13 athyreotic patients (6 males) during TSH suppressive 
therapy and after 4 weeks of thyroid hormone withdrawal. A magnetic bead capture system 
was used to isolate 384 defined miRNAs from serum. Subsequently, the TaqMan Array Card 
3.0 platform was used for profiling after individual target amplification.
Results: Mean age of the subjects was 44.0 years (range 20-61 years). Median TSH levels 
were 88.9 mU/l during levothyroxine withdrawal and 0.006 mU/l during LT4 treatment with 
a median dosage of 2.1 µg/kg. After normalization to allow inter-sample analysis, a paired 
analysis did not demonstrate a significant difference in expression of any of the 384 miRNAs 
analyzed on and off LT4 treatment.
Conclusion: Although we previously showed an up-regulation of pri-miRNAs 133b and 
206 in hypothyroid state in skeletal muscle, the present study does not supply evidence that 
thyroid state also affects serum miRNAs in humans. 
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Introduction
Hypothyroidism is one of the most common endocrine disorders (1). Despite adequate 
restoration of biochemical euthyroidism with levothyroxine (LT4) replacement therapy, a 
substantial proportion of patients (~10-15%) display significant impairment of psychological 
well-being compared to controls of similar age and sex and show decrements in health status 
(2-4). One of the explanations for this impaired well-being might be the inadequacy of LT4 
treatment to restore physiological thyroxine (T4) and triiodothyronine (T3) concentrations, 
especially the T4/T3 ratio, in serum and tissues (5, 6). Studies in hypothyroid rats showed that 
LT4 monotherapy was unable to normalize concentrations of T4 and T3 in all tissues (7). The 
LT4 dose needed to normalize thyroid hormone concentrations was tissue-dependent, and 
supra-physiological serum T4 concentrations had to be reached in most tissues to normalize 
their local T3 concentrations. 
Serum TSH concentrations, reflecting the pituitary feedback to thyroid hormone, is used in 
clinical practice to monitor LT4 treatment because it is the best available marker of thyroid 
state. However, although TSH typically reflects local T3 concentrations in the pituitary, it 
may not necessarily reflect local thyroid status in all tissues, especially when thyroid hormone 
production is not endogenously controlled, such as in athyreotic patients during LT4 therapy 
(8, 9). For this reason, novel markers representing thyroid state of other tissues than the 
pituitary would be of great clinical relevance.  
MicroRNAs (miRNAs) are non-coding RNA molecules with a length of approximately 22 
nucleotides, which predominantly post-transcriptionally repress the translation of mRNAs 
from target genes by binding to the 3’UTR of messenger RNA (10-12). Overall, miRNAs 
exhibit tissue-specific expression patterns and each miRNA may affect the expression 
of hundreds of target genes. Recently, we reported on gene expression profiles in skeletal 
muscle of hypothyroid patients off and on LT4 therapy and found a large up-regulation in 
expression of the muscle-specific pri-miRNAs 133b and 206 in hypothyroid state (13). This 
was supported by other studies that found an increase in expression of miRNAs- 1, 206, 133a 
and 133b in livers of hypothyroid mice compared to euthyroid controls (14). MiRNAs are also 
present in the circulation and have been associated with a variety of diseases (15, 16). We 
therefore hypothesized that miRNA profiles in serum can also be influenced by thyroid state, 
and that miRNAs derived from different tissues potentially reflect tissue-specific differences 
in thyroid states. 
Materials and methods
Patients
Patients with differentiated thyroid cancer (DTC) are exposed to different thyroid states as 
part of their treatment. These patients are subject to severe hypothyroidism before radioactive 
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iodine (RAI) therapy to stimulate radioactive iodine uptake by malignant tissues, whereas they 
have relatively high thyroid hormone concentrations afterwards when receiving substitution 
therapy with LT4 to suppress TSH. As a consequence, these patients are an ideal model to 
study the consequences of different thyroid states longitudinally. Therefore, we used patients 
with DTC as a model to quantify serum levels of 384 miRNAs in different thyroid states.
13 DTC patients were consecutively recruited from the outpatient clinic of the Erasmus Medical 
Center, between May 1st 2013 and February 1st 2015. Patients were eligible for inclusion if they 
needed RAI therapy during LT4 withdrawal according to the Dutch guidelines (17), had no 
other malignancies or an active inflammatory disease, and were between 18 and 80 years old.
The study protocol was approved by the Medical Ethics Committee of the Erasmus Medical 
Center (MEC 2012-561) and written informed consent was obtained from all study participants.
Thyroid function measurements
Peripheral blood samples were obtained in non-fasting conditions from all participants on 
and off LT4 treatment. Serum Free T4 (FT4, reference range 11-25 pmol/L) and total T3 
(reference range 1.4-2.5 nmol/L) concentrations were measured by chemoluminescence 
assays (Vitros ECI Immunodiagnostic System; Ortho-Clinical Diagnostics, Rochester, MI). 
Serum TSH concentration (reference range 0.4-4.3 mU/L) was determined by immunometric 
assay (Immulite 2000 XPi, Siemens, Den Haag, the Netherlands). Serum samples were stored 
at −80 °C until further analysis of miRNAs.
miRNA isolation from serum
The method of miRNA isolation and quantification has been previously described extensively 
(18). In short, the miRNAs were purified from serum samples using TaqMan ABC Purification 
Kit – Human Panel A (Thermo Fisher, PN 4473087). These panels consist of superparamagnetic 
Dynabeads covalently bound to a unique set of 384 anti-miRNA oligonucleotides. The miRNAs 
match the miRNAs in Megaplex Pool described below. The panel includes exogenous and 
endogenous controls. Briefly, 100 µL of lysis buffer was added to 50 µL of serum. One µL of 1 
nM of a non-human external control (ath-miRNA-159a) was added to monitor the extraction 
process, followed by the addition of 80 µL of beads (80 × 106 beads). The tubes were mixed for 
40 min at 1200 rpm and 30 °C, the beads were isolated using a magnetic bead separator, and 
washed three times with wash buffer. The bound miRNAs were eluted from the beads with 
100 µL elution buffer and incubated at 70 °C for 3 min. The eluted miRNA pool was stored at 
−80 °C until ready to use.
For miRNA profiling, Megaplex Primer Pool A was used in conjunction with the matching 
TaqMan miRNA Array Card A. All reagents were purchased from Thermo Fisher/Life 
Technologies (Bleiswijk, NL). Briefly, 3 µL of the miRNA sample isolated with the ABC kit 
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was reverse transcribed with the Megaplex RT Primer Pool A (PN 4399966) in a 8 µL final 
volume. The RT reaction was performed under thermal cycling (2 min at 16 °C, 1 min at 42 
°C, 1 sec at 50 °C, for 40 cycles) and the enzyme was inactivated by treatment for 5 min at 85 
°C. Four µL RT reaction was combined with its matching Megaplex PreAmp Primer Pool (PN 
4399233) and TaqMan PreAmp Master Mix (PN 4391128) in a final volume of 25 µL. Pre-
amplification was done using the following cycling conditions: 10 min at 95 °C; 2 min at 55 
°C; 2 min at 72 °C; 15 sec at 95 °C, 4 min at 60 °C for 12 cycles; 99 °C for 10 min. The final pre-
amplification product was diluted 1:100 in 1X TaqMan Universal Master Mix (PN 4364341), 
then loaded onto the matching TaqMan MiRNA Array Card A (PN 4398965) and run on a 
TaqMan® 7900HT Fast Real-Time PCR System under universal cycling conditions.
miRNA quantification
Raw data files were imported and analyzed using ExpressionSuite v1.0.4 (Life Technologies, 
South San Francisco, CA, USA), a software data analysis tool that can easily import and 
analyze large raw data files. In these experiments, the quantification cycle (Cq) is defined as 
the fractional cycle at which the amplification plot crosses the fluorescence threshold (Ct). 
The baseline was set automatically and the threshold was manually set at 0.2 and adjusted 
whenever appropriate to get an intersection in the exponential part of the curve. To capture 
as many differentially expressed miRNAs as possible, the threshold was set at 40 instead 
of 30–32 which is generally recommended by Life Technologies for relatively high miRNA 
levels. Undetermined values were replaced with the maximal number of cycles (=40) (19). 
The miRNAs with a Ct value of 40 in ≥ 75% of the samples were removed from the dataset. 
The non-human external control (ath-miRNA 159a) differed between the serum samples with 
Ct values ranging between 23.0 and 26.9 (mean Ct value 24.4; SD 0.96). In previous studies 
using the same protocol, variation in spike-in controls has been reported to be similar (20). 
To allow comparison between the individual samples, calibration and normalization was 
performed using global normalization according to Mestdagh et al.(21). A second method 
for normalization, also using endogenous controls, was performed. Based on an established 
algorithm for stability analysis (Normfinder), miRNA 93 and miRNA 130a turned out to 
be the most stable combination of miRNAs with mean Ct values (±SD) of 28.3 (±0.58) and 
30.5 (±0.6) respectively (22). Normalization was also performed using the mean of these 
normalizers. 
Software and statistics
Data were extracted using ExpressionSuite v1.0.4 (Life Technologies/Applied Biosystems). 
Data pre-processing was performed in Microsoft Excel 2010. Statistical analysis was 
performed using SPSS Statistics for Windows, version 21 (IBM Corp., Armonk, NY, USA). The 
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Wilcoxon signed rank test was used for paired comparison of  miRNA expression (∆Ct) and 
thyroid function tests on and off LT4 treatment. Multiple comparison adjustment was applied 
using the FDR approach (23).  
Results
Characteristics of 13 study patients are shown in Table 1. Mean age was 44.0 years (±SD 
11.1) and mean BMI was 30.0 kg/m2 (±SD 6.0). Three of the patients (subjects 11-13) were 
treated with remnant ablation RAI therapy 4 weeks after thyroidectomy while the others were 
prepared for an extra RAI treatment by thyroid hormone withdrawal because of (suspicion of) 
residual or recurrent disease or positive anti-thyroglobulin (anti-Tg) antibodies. 
As expected, thyroid function tests were significantly different on and off LT4 treatment (Table 
2), reaching low levels of total T3 and FT4 with elevated TSH levels off LT4 replacement. 
Table 1. Baseline characteristics
Subject Age Sex BMI
(kg/m2)
Type 
of 
tumor
Comorbidity
Number 
of RAI 
treatments
Tg-off 
(µg/l)
Post-
therapy 
I131 scan
1 49 Male 25.8 PTC Pulmonary embolism 1 3.9 No uptake
2 51 Female 34.1 PTC none 1 2.1 No uptake
3 34 Male 36.4 PTC none 4 517.0 Sacral metastasis
4 47 Female 32.9 PTC hypoparathyroidism 1 94.4 No uptake
5 50 Male 24.5 PTC none 3 5.6 LN
6 20 Female 20.7 PTC hypoparathyroidism 1 <0.9* No uptake
7 37 Female 24.6 PTC none 2 21.8 Mediastinal LN
8 39 Male 40.5 PTC none 3 12.9 No uptake
9 58 Female 29.0 FTC none 1 <0.9 Not performed
10 61 Female 26.7 PTC hypertension 1 21.6 No uptake
11 48 Female 35.1 PTC hypertension 0 <0.9* Thyroid remnant
12 45 Male 34.9 PTC hypertension 0 7.5 Thyroid remnant
13 33 Male 25.0 PTC none 0 <0.9* Thyroid remnant
PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; BMI, body mass index; RAI, radioactive iodine; Tg, 
thyroglobulin; LN, lymph node. *anti-Tg positive
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Table 2. Thyroid function tests
Off LT4 On LT4 P
TSH (0.4-4.3 mU/l) 88.9 (56.5-118.5) 0.006 (0.004-0.015) 0.001
Total T3 (1.4-2.5 nmol/l) 0.64 (0.58-0.70) 2.13 (2.0-2.3) 0.001
Free T4 (11.0-25.0 pmol/l) 1.6 (0.4-1.8) 25.7 (22.4-29.3) 0.001
Dosage LT4 (µg/kg) 2.1 (1.9-2.6)
Time between tests, weeks (range) 24.7 (11.0-38.8)
Changes in thyroid function tests (normal range) off and on LT4 treatment. Data are presented as median with 
interquartile range. LT4, levothyroxine; TSH, thyroid stimulating hormone; T3, triiodothyronine.
Profiling of miRNAs 
Out of the 384 miRNAs analyzed, almost half showed very low to undetectable  levels. 
After removing all miRNAs with Ct values of 40 in ≥ 75% of the samples, only 195 miRNAs 
remained for analysis. Supplemental table 1 shows the fifty most abundant miRNAs in serum 
on and off LT4. After calibration and normalization on the global mean, the statistical analysis 
revealed that none of the miRNAs was significantly altered between different thyroid states 
after correction for multiple testing (Fig 1). As a complementary approach, we normalized 
the dataset on the mean levels of two endogenous reference miRNAs (miRNA 93 and miRNA 
130a). This confirmed the absence of any significant differences in expression of any of the 
miRNAs analyzed between thyroid states (data not shown). 
MiRNAs
FD
R
 a
dj
us
te
d
P-
va
lu
e
P-value treshold
Figure 1. Scatterplot showing the false discovery rate (FDR) adjusted p-value for each miRNA separately. 
The dashed line represents the FDR significance threshold.
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Previously reported miRNAs
The profiles of miRNAs which have been previously reported to be differentially expressed in 
muscle and liver in hypothyroidism were evaluated (13, 14). The level of miRNA 1 was mostly 
undetectable and showed a mean Ct value of 39.1 (±2.1) in hypothyroid state versus 38.0 
(±2.3) in hyperthyroid state (not significant). MiRNA 206 was not on the card. MiRNA 133a 
showed a mean Ct value of 31.2 (±1.2) in hypothyroid state versus 31.3 (±1.7) in hyperthyroid 
state. MiRNA 133b was also mostly undetectable with a mean Ct value of 38.7 (±2.9) in 
hypothyroid state versus 37.9 (±3.0) in hyperthyroid state (not significant).
Discussion 
To our knowledge, this is the first study investigating a selected multi-target miRNA profile 
in serum of individual patients during (extreme) changes in thyroid states. Most studies 
on miRNAs in patients with thyroid disease have focused on thyroid cancer (24). A study 
by Yamada et al, reported several miRNA levels that were differently expressed in serum 
from patients with autoimmune thyroid disease compared with healthy subjects (25). They 
suggested that the underlying autoimmune condition was responsible for the observed changes 
since there was no association between the mentioned miRNAs and TSH levels. However they 
did not study the changes in miRNA expression after restoring euthyroidism (25). Another 
study demonstrated that different levels of circulating miRNAs are associated with intractable 
Graves’ disease compared with Graves’ disease in remission (26).
In our study, we could not find significant changes in expression of serum miRNAs in 
athyreotic hypothyroid patients on and off LT4 treatment, despite previous studies showing 
clear differences in (precursors of) miRNAs in different tissues (13, 14, 27). There are a number 
of possible explanations for our results. First, our sample size might have been too small to 
discover significant changes in miRNA expression levels. However, previously, in a cohort of 
similar size, microarray analysis revealed large differences between thyroid states in muscle 
samples, suggesting that the used sample size was sufficient if the differences would have 
been equally large and consistent (13). McDonald et al. found that assay imprecision (due to 
variability in the RNA extraction process and interassay imprecision) had significant effects 
on the reproducibility of miRNA measurements and concluded that only miRNAs that are 
extremely up- or downregulated will be suitable as clinical biomarkers (28). If there were such 
extremely up- or downregulated miRNAs they should have been detected in our sample size. 
Second, although it has been shown that miRNAs are present in human plasma and serum in 
a remarkably stable form that is protected from endogenous RNase activity (15), differences in 
the time between blood drawing and storage potentially impact on the miRNA levels released 
from blood cells, in particular if samples are stored over 24h (28). However, all our samples 
were stored at -80 °C within 2 to 4 hours of collection and therefore a significant effect on 
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miRNA expression is not likely (29). Third,  although after calibration, normalization of the 
data was performed using two different methods (based on the global mean and based on mean 
levels of two endogenous reference miRNAs) providing similar results, we cannot rule out that 
a variation in protocol efficiency might have influenced our results. Finally, although several 
studies have shown that thyroid hormones seem to regulate miRNA expression in several 
organs such as skeletal muscle, liver and heart, these changes in tissue miRNA expression may 
not be reflected in serum (13, 14, 27). It has to be mentioned that our previous study in muscle 
samples examined only precursors of mature miRNAs (pri-miRNAs) while our current study 
investigated the effects of TH on the levels of mature miRNAs. However, Dong et al. found 
significant decreases of both mature miRNAs and it’s corresponding precursor miRNAs in 
liver samples of hypothyroid mice compared to euthyroid controls (14). 
Our study has several strengths and limitations. A limitation of our study is that we only 
studied a selection of 384 miRNAs and we cannot rule out that other miRNAs, which were not 
included in our platform are influenced by thyroid state. For example, miRNA 206, of which 
the precursor pri-miRNA-206 differed significantly in skeletal muscle, was not included in 
the current platform. A possible confounder of our study is that we studied patients with DTC, 
while several miRNAs in serum have been postulated as biomarker for DTC (24). Although 
seven of our patients did not show any uptake on the post-therapy RAI scan and Tg-off  levels 
were mostly low, some miRNAs theoretically could have been changed by the response of the 
tumor to RAI therapy or to the radiation it selves. Our study has several strengths as well. First, 
the study design included paired analyses, which has the advantage to reduce confounders. 
Second, we were able to study extreme differences in thyroid state in human subjects. Finally, 
we used a validated and widely used method to generate the serum miRNA profile (19, 30-32). 
In conclusion, although we previously showed regulation of pri-miRNAs by thyroid hormone 
in muscle samples, the present study using an extensive panel of 384 miRNAs does not supply 
evidence of regulation of mature miRNAs in serum by thyroid hormone. 
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Supplemental Table 1. Fifty most abundant miRNAs in serum off and on levothyroxine (LT4)
off LT4
mean 
Ct value range on LT4
mean 
Ct value range
miRNA 223 18.4 (15.9-19.5) miRNA 223 18.9 (17.2- 20.5)
miRNA 451 21.9 (20.8-23.7) miRNA 451 22.3 (19.1- 24.7)
miRNA 16 22.7 (21.6-24.0) miRNA 16 23.2 (21.6-24.4)
miRNA 126 24.5 (23.8-25.3) miRNA 126 24.6 (23.7-25.7)
miRNA 92a 24.6 (23.9-25.2) miRNA 92a 24.7 (23.6-26.1)
miRNA 19b 24.7 (22.9-25.6) miRNA 19b 24.8 (23.5-26.1)
miRNA 191 24.7 (23.7-25.5) miRNA 146a 25.0 (23.6-26.4)
miRNA 17 24.8 (24.0-25.5) miRNA 191 25.0 (24.0-26.4)
miRNA 106a 24.8 (23.8-25.6) miRNA 17 25.0 (24.1-25.5)
miRNA 24 24.9 (24.2-26.5) miRNA 106a 25.1 (23.7-26.5)
miRNA 146a 25.0 (23.7-26.5) miRNA 484 25.4 (23.9-27.0)
miRNA 20a 25.3 (24.4-26.5) miRNA 24 25.5 (23.7-27.7)
miRNA 484 25.4 (23.2-26.5) miRNA 20a 25.7 (24.7-26.6)
miRNA 150 25.9 (23.4-28.5) miRNA 30c 26.3 (24.6-28.4)
miRNA 30c 26.3 (25.2-27.5) miRNA 30b 26.6 (25.7-27.6)
miRNA 30b 26.7 (26.0-27.8) miRNA 150 26.8 (25.1-27.9)
miRNA 26a 26.9 (26.1-27.7) miRNA 21 26.9 (26.1-27.8)
miRNA 320 27.0 (25.5-28.5) miRNA 222 27.1 (25.9-28.5)
miRNA 197 27.1 (25.7-28.6) miRNA 320 27.3 (26.5-28.3)
miRNA 222 27.1 (25.6-29.3) miRNA 26a 27.3 (26.1-32.7)
miRNA 21 27.1 (26.0-27.8) miRNA 197 27.5 (26.0-29.6)
miRNA 3423p 27.4 (26.3-28.6) miRNA 3423p 27.7 (26.9-28.7)
miRNA 25 27.4 (26.5-28.2) miRNA 25 28.0 (26.3-29.4)
let7b 27.9 (25.7-30.5) miRNA 15b 28.1 (27.5-29.4)
miRNA 26b 28.0 (26.9-29.5) let7e 28.2 (27.0-29.6)
miRNA 15b 28.0 (26.5-30.6) miRNA 26b 28.3 (27.0-29.6)
miRNA 93 28.2 (27.5-28.6) miRNA 93 28.4 (27.4-29.6)
miRNA 106b 28.4 (27.5-29.5) let7b 28.4 (26.6-32.2)
let7e 28.5 (26.9-29.7) miRNA 221 28.4 (27.5-29.7)
miRNA 3313p 28.6 (27.4-29.6) miRNA 3313p 28.6 (26.7-29.7)
miRNA 146b5p 28.7 (27.7-29.5) miRNA 106b 28.7 (27.7-29.6)
miRNA 221 28.8 (28.4-28.6) miRNA 1395p 28.7 (26.6-30.5)
miRNA 5743p 28.8 (26.8-30.5) miRNA 145 28.9 (27.6-29.6)
miRNA 122 28.9 (26.5-30.5) miRNA 5743p 29.0 (27.3-31.5)
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Supplemental Table 1. Fifty most abundant miRNAs in serum off and on levothyroxine (LT4) 
(Continued)
off LT4
mean 
Ct value range on LT4
mean 
Ct value range
miRNA 374b 29.0 (27.5-29.5) miRNA 122 29.0 (27.1-30.6)
miRNA 145 29.0 (27.9-30.6) miRNA 146b5p 29.1 (28.4-29.6)
miRNA 1395p 29.2 (27.5-31.0) miRNA 148a 29.2 (27.5-30.6)
miRNA 8855p 29.3 (27.5-30.5) miRNA 328 29.3 (28.0-31.6)
miRNA 29a 29.3 (27.8-30.7) miRNA 660 29.3 (27.8-31.7)
miRNA 186 29.4 (28.0-30.5) miRNA 374b 29.4 (28.5-30.6)
miRNA 20b 29.5 (28.1-30.6) miRNA 199a3p 29.5 (28.0-30.4)
miRNA 103 29.5 (27.4-38.6) miRNA 29a 29.6 (27.0-31.4)
miRNA 199a3p 29.6 (28.6-30.6) miRNA 186 29.8 (28.6-30.7)
miRNA 148a 29.6 (28.6-30.8) miRNA 20b 29.9 (28.5-30.6)
miRNA 328 29.6 (28.1-31.5) miRNA 19a 30.0 (28.7-30.9)
miRNA 660 29.6 (28.5-30.6) miRNA 195 30.1 (27.7-31.5)
miRNA 195 29.8 (28.5-32.4) miRNA 103 30.1 (28.1-40)
miRNA 19a 30.0 (29.0-31.6) miRNA 8855p 30.1 (28.9-31.6)
miRNA 335 30.2 (28.5-31.7) miRNA 27a 30.1 (29.1-35.7)
let7g 30.2 (28.0-33.6) let7g 30.2 (27.8-32.0)
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Abstract
Context: Despite the well-recognized clinical features due to insufficient or excessive thyroid 
hormone (TH) levels in humans, it is largely unknown which genes are regulated by TH in 
human tissues. 
Objective: To study the effect of TH on human gene expression profiles in whole blood, 
mainly consisting of TRα-expressing cells.
Methods: We performed next-generation RNA sequencing on whole blood samples from 
8 athyroid patients (4 females) on and after 4 weeks off levothyroxine replacement. Gene 
expression changes were analyzed through paired differential expression analysis and 
confirmed in a validation cohort. Weighted gene co-expression network analysis (WGCNA) 
was applied to identify thyroid state-related networks.
Results: We detected 486 differentially expressed (DE) genes (fold-change above 1.5; multiple 
testing corrected P-value <0.05), of which 76 % were positively and 24 % were negatively 
regulated. Gene ontology (GO) enrichment analysis revealed that 7 biological processes 
were significantly overrepresented of which the process translational elongation showed the 
highest fold enrichment (7.3 fold, P=1.8 x 10-6). Comparative transcriptome analysis revealed 
significant overlap with DE-genes in muscle samples upon different thyroid state (2.3-fold 
enrichment; P=4.1 x 10-5). WGCNA analysis independently identified various gene clusters 
that correlated with thyroid state. Further GO-analysis suggested that TH regulates platelet 
function. 
Conclusions: Changes in thyroid state regulate numerous genes in human whole blood, 
predominantly TRα-expressing leukocytes. In addition, TH may regulate gene expression in 
platelets. Whole blood samples can potentially be used as a proxy for other TRα-expressing 
tissues in humans. 
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Introduction
Thyroid hormone (TH) affects virtually all cells and tissues in the human body. The major 
biologically active TH is T3 and its genomic actions are mediated by binding to nuclear T3 
receptors (TRs) which regulate transcription of target genes (1). Several receptor isoforms are 
encoded by the THRA and THRB genes of which TRα1, TRβ1 and TRβ2 are the truly T3 binding 
isoforms (2). The TR isoforms have a distinct expression pattern, with a predominance of TRα1 
in brain, heart and bone and TRβ1 in the liver, kidney and thyroid. TRβ2 is mainly expressed 
in hypothalamus and pituitary and is, thus, involved in the regulation of the hypothalamus-
pituitary-thyroid axis (3). 
Despite the classical clinical features due to insufficient or excessive TH levels which have 
been recognized for over 100 years, the underlying molecular mechanisms in humans are 
not well understood. Knowledge of gene expression modulated by TH is largely derived from 
animal models or in vitro cellular studies used to explore which genes are regulated by TH (4-
7). Expanding knowledge of the effects of TH on gene expression in human tissues will provide 
more insight in the molecular basis of TH action and may lead to a better understanding of the 
clinical effects of TH in humans.
Progress is limited because most human tissues are not easily accessible. However, blood 
can be regarded as circulating tissue and contains various cell types including erythrocytes, 
leukocytes and platelets (8). RNA in whole blood is largely determined by leukocytes, which 
mainly express the TRα isoform (9). Therefore, analysis of gene expression in whole blood 
may potentially be used as proxy for other TRα-expressing tissues. To study the effects of 
TH on gene expression in human TRα-expressing cells we performed next generation RNA 
sequencing (RNA-Seq) in whole blood cells from athyroid patients off and on levothyroxine 
(LT4) treatment. 
Patients and Methods
Patients
Patients were recruited via the outpatient clinic of the Erasmus Medical Center, which is a 
tertiary referral center for differentiated thyroid cancer (DTC). Patients with DTC undergoing 
TSH-stimulated 131I therapy after withdrawal of LT4 were asked to participate in the study. 
Patients were eligible for inclusion if they had no other malignancies or an active inflammatory 
disease, were not using any drugs known to influence TH metabolism, and were between 18 
and 80 years old. A discovery and a validation cohort were created according to the same 
protocol. 
The study protocol was approved by the Medical Ethics Committee of the Erasmus Medical 
Center (MEC 2012-561). Written informed consent was obtained from all study participants.
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Sample collection and serum analyses
Peripheral blood samples were obtained from all participants when overt biochemical 
hypothyroidism was achieved by withdrawal of LT4 substitution in thyroidectomized 
patients as well as when TSH suppression was achieved after restarting LT4 replacement 
therapy. Serum free T4 (FT4, reference  range 11-25 pmol/l), total T4 (reference range 58-
128 nmol/l) and total T3 (reference range 1.4-2.5 nmol/l) concentrations were measured 
by chemoluminescence assays (Vitros ECI Immunodiagnostic System; Ortho-Clinical 
Diagnostics, Rochester, MI). Serum TSH (reference  range 0.4-4.3 mU/l) was measured by 
an immunometric assay (Immulite 2000 XPi, Siemens, Den Haag, the Netherlands). Whole 
blood samples were collected in PAXgene tubes. PAXgene tubes contain a proprietary reagent 
that immediately stabilizes intracellular mRNA, thus reducing mRNA degradation and 
inhibiting gene induction after phlebotomy. The isolated mRNA represents all blood cells, 
including polymorph nuclear leukocytes, mononuclear cells, platelets and red blood cells (10).
RNA was isolated using PAXgene blood miRNA kits (PreAnalytiX, Hombrechtikon, Switzerland). 
For RNAseq analysis of the discovery cohort, ribosomal RNA and globin mRNAs were first 
removed from an aliquot of the RNA samples using the Globin-Zero Gold rRNA Removal Kit 
(Illumina, San Diego, USA) (11). Kapa Stranded RNA library was prepared (Kapa Stranded 
RNA kit, Kapabiosystems), followed by sequencing on a HiSeq2500 system, for single end 
reads, 50 bp in length (Illumina, USA). 
Bioinformatic analysis
We analyzed genes with at least 5 reads in at least 6 samples. The generated sequencing 
reads were aligned (stranded alignment) against the GRCh38 version of the human reference 
genome, with RefSeq gene annotation, using Tophat2 (12). Gene counts were generated from 
the BAM files with HTseq (13). Cufflinks was used to compute transcript abundance estimates 
in fragments per kilo base of transcript per million mapped reads (FPKMs) (14). Differential 
expression was calculated with the bioinformatics tool DESeq 2 from Bioconductor, which uses 
the R statistical programming language (15). Cut off values for significantly expressed genes 
were a false discovery rate of 0.05 or less and a fold change of 1.5. To visualize the clustering 
of the samples, principal component analysis (PCA) was performed. The normalized data 
file was transposed and imported into OmniViz version 6.1.13 (Instem Scientific, Inc., Stone, 
Staffordshire, UK) for further analysis. The geometric mean of the intensity of all samples 
was calculated. The level of expression of each gene was determined relative to this geometric 
mean and 2log transformed.. The geometric mean of all samples was used to ascribe equal 
weight to gene expression levels with similar relative distances to the geometric mean. The 
data were deposited in NCBI/GEO reference (URL) and Accession number GSE103305.
We used functional enrichment analysis to explore the biological significance of DE-genes 
and of genes in WGCNA-modules (see below) using DAVID (EASE) (16). DAVID calculates 
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significantly overrepresentation of gene ontology (GO)-classified biological processes by 
comparing the number of genes in a gene list for a biological process to the number of genes 
for that biological process from the RNA-Seq analysis (17). Biological processes are shown 
which were significantly enriched after correction for multiple testing. 
Quantative PCR (qPCR)
To confirm the RNA-Seq results by an independent technique, qPCR was used to measure 
expression of selected genes. QPCR was performed on cDNA produced from RNA before 
applying Globin-Zero Gold rRNA Removal Kits on the discovery cohort and on cDNA from the 
validation cohort. The primer sequences are presented in Supplemental Table 1. RNA levels 
are expressed relative to the geometric mean of the house-keeping genes GAPDH and ACTB.
Table 1. Thyroid function tests and leukocyte counts
Off LT4 On LT4 P
TSH (mU/l) 78.0 (48.5-117.5) 0.07 (0.004-0.11) 0.012
Total T3 (nmol/l) 0.72 (0.63-0.83) 2.11 (1.94-2.28) 0.012
Total T4 (nmol/l) 17.0 (14.0-18.0) 155.0 (135.5-170.5) 0.018
FT4 (pmol/l) 1.55 (1.12-2.17) 26.2 (22.3-29.5) 0.012
Leukocytes (x109/l) 7.6 (5.5- 8.1) 7.4 (5.5-8.7) 0.26
Neutrophils (%) 60.0 (52.0-67.0) 62.8 (58.2-65.7) 0.50
Lymphocytes (%) 32.4 (25.1-35.9) 27.3 (23.5- 28.6) 0.13
Monocytes (%) 4.7 (4.6- 7.8) 8.1 (6.9-9.6) 0.018
Dosage LT4 (µg/kg) 2.3 (2.0-2.7)
Time between tests (wks) 22.5 (17.2-24.0)
Thyroid function tests and leukocyte counts off and on LT4 replacement. Data are expressed as median with IQR. Data 
were compared using the Wilcoxon signed rank test.
Statistical analysis
Likelihood and significance of the overlap with DE-genes in muscle samples off and on LT4 
treatment previously reported were tested using the χ2-test (18). Thyroid function tests and 
leukocyte counts were compared off and on LT4 treatment using the Wilcoxon signed rank 
test. Statistical analysis was performed using SPSS Statistics for Windows, version 22 (IBM 
Corp., Armonk, NY, USA).
Weighted gene co-expression network analysis
We performed a weighted gene co-expression network analysis (WGCNA) to discover co-
expressed TH-related networks (modules) (19, 20). In short, a weighted adjacency matrix 
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containing pair-wise connection strengths was constructed by using the soft-thresholding 
approach (β = 6) on the matrix of pair-wise correlation coefficients. A connectivity measure 
(k) per gene was calculated by summing the connection strengths with other genes. Modules 
were defined as branches of a hierarchical clustering tree using a dissimilarity measure (1 - 
topological overlap matrix) (20, 21). Each module was subsequently assigned a color. The 
gene expression profiles of each module were summarized by the module eigengene (defined 
as the first principal component of the module expression levels). Each module eigengene was 
correlated to thyroid status (with age, BMI, gender, leukocytes and leukocyte differentiation 
as covariates) using the WGCNA R package (FDR 5%). 
Results
Study population
We studied whole blood samples from 8 athyroid patients (4 females and 4 males) off and on 
LT4 treatment. Characteristics of the patients are shown in Supplemental Table 2. Table 1 shows 
the serum TH concentrations and total leukocyte counts, including leukocyte differentiation, 
off and on LT4 treatment. As expected, the thyroid function tests were significantly different. 
Neither total leukocyte counts nor leukocyte differentiation showed significant differences, 
except for a slight increase in monocyte number during LT4 treatment.
Validation of selected genes 
To validate the RNA-Seq data from the discovery cohort, qPCR was used as an independent 
technique to measure the relative expression of selected DE genes. Genes were selected based 
on robust baseline expression, robust fold change in expression and low adjusted p-value. All 
upregulated and most downregulated genes showed significant differential expression using 
qPCR (Figure 2). We validated our findings in an independent cohort of which the baseline 
characteristics are shown in Supplemental Table 4. qPCR analysis of  the validation cohort 
confirmed that all genes were similarly regulated by TH as in the discovery cohort, although 
this was not significant for some small nucleolar RNAs (snoRNAs) and PDE5A (Figure 2). 
Standard gene expression analysis
To assess the effects of thyroid state on gene expression in whole blood cells, we performed 
next-generation RNA-Seq on samples drawn from patients off and on LT4 replacement 
therapy. At least 15 million reads were generated for each sample and approximately 95% of 
these reads were aligned. We first quantified both TR isoforms to confirm that TRα is the main 
receptor isoform expressed in whole blood samples (Figure 1A). After filtering for expressed 
genes, 16014 genes remained for analysis. PCA analysis showed a high degree of clustering 
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of patients off and on LT4 treatment. We detected 1227 differentially expressed (DE) genes 
(multiple testing corrected P value < 0.05). We selected 486 DE-genes with an absolute fold-
change above 1.5 (Supplemental Table 3), shown as hierarchical clustering in Figure 1B. This 
indicates that thyroid hormone has both positive and negative effects on gene regulation (76 
% upregulated; 24 % downregulated). The 47 genes that differed at least 2-fold in expression 
are presented in Table 2. 
Table 2. Genes that differed 2-fold in expression (2log ratio >1 or < -1)
2Log ratio Molecules P adj. Description
Upregulated genes 
1.824 CCNJL 2.0 x 10-24 Cyclin J-Like
1.377 SHISA4 5.1 x 10-6 Shisa Family Member 4
1.342 PLVAP 2.6 x 10-6 Plasmalemma Vesicle Associated Protein
1.257 PDE5A 9.4 x 10-8 Phosphodiesterase 5A
1.247 RIOK3 5.6 x 10-8 RIO Kinase 3 
1.247 TUBB1 7.8 x 10-8 Tubulin, Beta 1 Class VI
1.211 ARHGEF12 1.3 x 10-7 Rho Guanine Nucleotide Exchange Factor (GEF) 12
1.193 SH3BGRL2 5.7 x 10-7 SH3 Domain Binding Glutamate-Rich Protein Like 2
1.179 LINC00989 7.3 x 10-6 Long Intergenic Non-Protein Coding RNA 989
1.172 DAAM2 0.00012 Dishevelled Associated Activator Of Morphogenesis 2
1.169 CA2 6.2 x 10-6 Carbonic Anhydrase II
1.168 CTTN 2.1 x 10-6 Cortactin
1.165 RNF182 0.00027 Ring Finger Protein 182
1.163 ITGA2B 2.7 x 10-6 Integrin, Alpha 2b
1.151 EIF2AK1 4.5 x 10-7 Eukaryotic Translation Initiation Factor 2-Alpha Kinase 1
1.139 RAB27B 2.1 x 10-6 RAB27B, Member RAS Oncogene Family
1.136 PROS1 4.8 x 10-5 Protein S (Alpha)
1.123 CXCR2P1 1.4 x 10-5 Chemokine (C-X-C Motif) Receptor 2 Pseudogene 1
1.114 ABCG2 7.8 x 10-5 ATP-Binding Cassette, Sub-Family G (WHITE), Member 2 
1.111 ITGB3 0.00014 Integrin, Beta 3 (Platelet Glycoprotein IIIa, Antigen CD61)
1.093 ARL4A 3.0 x 10-6 ADP-Ribosylation Factor-Like 4A
1.082 STON2 7.8 x 10-8 Stonin 2
1.081 CDKN1A 2.1 x 10-6 Cyclin-Dependent Kinase Inhibitor 1A 
1.075 CTNNAL1 0.0009 Catenin (Cadherin-Associated Protein), Alpha-Like 1
1.073 CTDSPL 6.7 x 10-6
CTD (Carboxy-Terminal Domain, RNA Polymerase II, 
Polypeptide A) Small Phosphatase-Like
1.073 MYLK 1.6 x 10-5 Myosin Light Chain Kinase
1.062 ITGB5 1.2 x 10-5 Integrin, Beta 5
1.059 TUBB2A 0.0011 Tubulin, Beta 2A Class IIa
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Table 2. Genes that differed 2-fold in expression (2log ratio >1 or < -1) (Continued)
2Log ratio Molecules P adj. Description
1.041 MFAP3L 4.4 x 10-6 Microfibrillar-Associated Protein 3-Like
1.031 MYOF 4.2 x 10-6 Myoferlin
1.030 GNAZ 6.2 x 10-6
Guanine Nucleotide Binding Protein (G Protein), Alpha Z 
Polypeptide 
1.030 RNF10 4.3 x 10-6 Ring Finger Protein 10
1.029 MKRN1 0.0008 Makorin Ring Finger Protein 1 
1.026 IFIT1B 0.0018 Interferon-Induced Protein With Tetratricopeptide Repeats 1B
1.025 LTBP1 6.5 x 10-5 Latent Transforming Growth Factor Beta Binding Protein 1 
1.020 MMD 4.2 x 10-6 Monocyte To Macrophage Differentiation-Associated
1.019 GNG11 4.8 x 10-5 Guanine Nucleotide Binding Protein (G Protein), Gamma 11
1.011 ELOVL7 2.9 x 10-5 ELOVL Fatty Acid Elongase 7
1.011 HORMAD1 8.4 x 10-5 HORMA Domain Containing 1
Downregulated genes
-1.014 SNORA80B 1.3 x 10-5 Small Nucleolar RNA, H/ACA Box 80B
-1.064 SCARNA21 1.8 x 10-6 Small Cajal Body-Specific RNA 21
-1.072 COL4A3 0.00017 Collagen, Type IV, Alpha 3
-1.091 SNORD10 2.4 x 10-8 Small Nucleolar RNA, C/D Box 10
-1.140 SNORA34 6.7 x 10-6 Small Nucleolar RNA, H/ACA Box 34
-1.167 SNORA71D 4.0 x 10-6 Small Nucleolar RNA, H/ACA Box 71D
-1.214 RPS18P9 1.1 x 10-6 Ribosomal Protein S18 Pseudogene 9
-1.397 SNORA49 6.3 x 10-9 Small Nucleolar RNA, H/ACA Box 49
- LT4 + LT4
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Figure 1. A. Gene expression (FPKMs) of TRα1 and TRβ1 off and on LT4 treatment. * P <0.05, **P<0.01, 
*** P<0.001. B. OmniViz Treescape shows the hierarchical clustering of DE-genes off and on LT4 
treatment.  Red: upregulated genes compared with the geometric mean; blue: downregulated genes 
compared with the geometric mean. The color intensity correlates with the degree of change. 
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Figure 2. Verification of RNAseq results by qPCR. 6 uregulated (A) and 6 downregulated genes (B) were 
selected from the RNAseq results. Results are shown as 2log ratio of the fold change in gene expression 
off and on LT4 treatment. * P <0.05, **P<0.01, *** P<0.001.
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Figure 3. GO enrichment analyses of DE-genes off and on LT4 treatment. The biological processes are 
shown on the Y axis. 
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GO analysis
Next, we analyzed whether the 486 DE-genes were associated with specific biological 
processes. GO enrichment analysis revealed that 7 biological processes were significantly 
overrepresented after correction for multiple testing (FDR 0.05) (Supplemental Table 5). 
Because some GO terms overlapped based on similar groups of genes, the number of biological 
processes was reduced to 3 (Figure 3). 
Comparative transcriptome analysis 
To explore to which extent gene expression in whole blood parallels gene expression in other 
tissues, we investigated the overlap with gene expression in skeletal muscle in different thyroid 
states (18). This dataset contained 607 DE-genes (fold-change > 1.5) in muscle samples off 
and on LT4 treatment as previously reported. Comparative transcriptome analysis of the 486 
DE-genes (fold-change > 1.5) of the present study with the muscle dataset revealed 26 genes 
that were shared between both tissues, which is a significant 2.3-fold enrichment (P=4.1 x 10-
5) (Supplemental Table 6). 
WGCNA 
To further explore TH-dependent transcriptional patterns in the current dataset, we employed 
WGCNA analysis. WGCNA can reveal the underlying organization of the transcriptome based 
on co-expression relationships. WGCNA complements traditional DE analyses by providing a 
system level framework for the understanding of transcriptional profiles. This has been shown 
particularly helpful in transcriptome analysis of samples composed of distinct cell and tissue 
types (22). 
Therefore, WGCNA is potentially useful to identify specific cell types responsive to different 
thyroid states. First, the genes showing most variability between samples (i.e. at least a 
2.0-fold change in level of expression from the global mean) were selected. This resulted in 
6649 genes, which were determined by their coefficient of variance, rather than any sample 
characteristics such as disease status. Subsequently, unsupervised hierarchical clustering 
led to the identification of 17 co-expression modules (Figure 4A). Modules correspond to 
branches and are color-coded, ranging in size from 67 genes in the light cyan module to 1737 
in the turquoise module (Supplemental Table 7). Next, modules were identified that were 
significantly associated with clinical parameters, including age, sex, leukocytes and thyroid 
state. Therefore, the summary file (eigengene) for each module was correlated with the clinical 
parameters to select the most significant associations (Figure 4B). The strength of WGCNA 
analysis is well exemplified by the tan module. The unbiased approach identified 120 genes in 
this module, which were closely linked according to WGCNA. Subsequent inspection learned 
that this module mainly contained genes expressed from the Y-chromosome. Regression 
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analysis afterwards correctly identified (male) sex to this module (r= 0.97, p= 2.0x 10-10). 
Using similar analysis, the blue and the midnight blue modules were significantly associated 
with thyroid state. The blue module correlated positively with thyroid state (r=0.65, p= 0.007) 
and contained numerous genes (213 of the 814 genes in this module) that were also found 
significantly regulated by TH in the DE analysis. The positive correlation reflects that most 
blue module genes were upregulated by TH. 
Next, we performed a GO enrichment analysis for the genes in the blue module (Supplemental 
Table 5). The biological process hemostasis was significantly enriched in the blue module. Of 
note, many genes in the blue module appeared transcripts expressed in platelets (e.g. P2RY12, 
PF4). The module midnight blue was negatively correlated with thyroid state (r= -0.78, p= 
4.0 x 10-4) and contained mostly genes (32 of the 74 genes) that were regulated by TH as 
well in the DE analysis, of which 26 (75%) were downregulated. Many genes in the module 
midnight blue belonged to the class of snoRNAs and it contained mostly genes without a GO 
annotation. Thus, WGNCA analysis suggested that gene expression not only in leukocytes but 
also in platelets is dependent on thyroid state. 
Figure 4.
Module-trait relationshipsCluster dendrogram
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Figure 4. A. Network construction identifies distinct modules of co-expressed genes. Modules of co-
expressed genes were assigned colors corresponding to the branches indicated by the horizontal bar 
beneath the dendrogram. B. Heatmap plot of the adjacencies in the eigengene network including several 
traits. Each row and column in the heatmap corresponds to one module eigengene (labeled by color) or 
trait (labeled on the x-axis). In the heatmap, green color represents low adjacency (negative correlation), 
while red represents high adjacency (positive correlation). The Blue and the Midnight Blue modules were 
significantly associated with thyroid state.
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Discussion
In humans, genes that are regulated by thyroid state are largely unknown. Previously, we 
and others discovered genes that are dependent on thyroid state in human skeletal muscle 
(18, 23). Ex vivo studies have identified T3-responsive genes in human skin fibroblasts and 
adipocytes (23-25). The present study identifies numerous genes in human whole blood 
samples that are regulated by thyroid state. Similar to previous transcriptome analysis studies, 
TH largely positively regulates gene expression, although a considerable number of genes is 
downregulated. As RNA from leukocytes is a major determinant to total RNA in blood (after 
removal of globin RNA), it is likely that the detected DE-genes largely represent the effects 
of thyroid state on leukocytes. Indeed, lymphocytes in peripheral blood have been shown to 
respond to T3 (26).  
To improve the yield of our genome-wide expression profiling, we performed WGCNA and 
compared these results with those of a standard analysis based on differential expression. 
While a standard analysis typically discloses lists of DE-genes, it fails to recognize the different 
connections between them. Indeed, WGCNA mapped many genes related to thyroid state into 
two large co-expression modules (modules blue and midnight blue). GO enrichment analyses 
of the TH-associated module blue showed  predominance of the biological process hemostasis 
of which the involved genes were upregulated by TH. Of note, many genes were platelet 
specific transcripts (e.g. P2RY12, PF4). The product of P2RY12 is a purinergic G-protein 
coupled receptor, which plays a crucial role in thrombus formation (27). P2RY12 inhibitors, 
such as clopidogrel and ticagrelor, have antithrombotic effects and are widely used in patients 
with acute coronary syndromes and in the secondary prevention of thrombotic events in 
vascular diseases (28). PF4 codes for a chemokine (platelet factor 4) which is synthesized 
in megakaryocytes and stored in platelet alpha granules. When platelets are activated, 
PF4 is released from the alpha granules facilitating thrombosis (29). The observation that 
circulating PF4 levels are decreased in patients with subclinical autoimmune hypothyroidism 
supports our findings (30). F13A1, another upregulated gene by TH, encodes the coagulation 
factor XIIIA subunit. Coagulation factor XIII is important for stabilisation of the fibrin clot. 
Together, these data suggest that TH induces transcription of pro-thrombotic genes. This is 
in line with the observation that hyperthyroidism increases the risk of thrombosis (31, 32). 
Even high-normal thyroid function within the reference range is associated with stroke, 
independent of classical cardiovascular risk factors (33). Previously, it has been shown that 
the production of several coagulation factors produced in the liver is enhanced  by TH (34, 35). 
Although we were unable to assess thrombocyte counts, other studies have demonstrated that 
platelet number is independent of thyroid state (36). The present study suggests that TH also 
positively regulates pro-thrombotic factors in platelets. 
The second WGCNA-module that correlated negatively with thyroid state was mainly 
composed of snoRNAs which were mostly downregulated by TH. SnoRNAs are classified 
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into two families (box C/D snoRNAs and box H/ACA snoRNAs) and are required for 
posttranscriptional modifications of ribosomal RNA (rRNA)(37). As the relationship between 
snoRNAs and TH has not been reported before, further studies are needed to understand the 
consequences of this finding. 
Although the effects of TH on peripheral blood cells (leukocytes, platelets) are of interest in 
itself (see above), we explored to which extent those findings were relevant for other tissues. 
As whole blood samples mainly contain TRα-expressing cells, our results likely reflect the 
effect of TH on gene expression via TRα. As TRα is abundantly expressed over TRβ in skeletal 
muscle, we sought to determine overlap between genes dependent on TH in muscle and genes 
identified in the present study. The significant overlap with the DE-genes from our previous 
study in muscle samples suggests that whole blood samples potentially can be used as a proxy 
for the effects of TH on other TRα-expressing tissues in humans (18). Obviously, extrapolating 
such findings should take into account that different factors influence TH bioactivity at the 
cellular level. Specifically, T3 concentrations at the pre-receptor level are importantly governed 
by cell-specific TH transporters and deiodinases. 
Several strengths and limitations are worth mentioning to provide context to our findings. 
A first limitation is that the observed changes in gene expression may not necessarily 
reflect direct effects of TH. Gene transcription may also be indirectly dependent on TH if 
it modulates intermediate signaling molecules. Second, one should realize that whole blood 
contains many different cell types. Although WGCNA was relevant in this context, other 
subtle changes may have gone unrecognized. Third, DE genes in hypothyroid versus mild 
thyreotoxic state (as in this study) are not necessarily the same DE genes as in hyperthyroid 
versus mild thyreotoxic state. Finally, since the patients adhered to an iodine deficient diet 
at the time of hypothyroidism, direct effects of changes in iodine state on gene expression 
cannot be excluded. Our study has several strengths. First, the study design included paired 
analyses, which has the advantage to reduce confounders and variability. Second, the results 
were confirmed in an independent cohort, substantiating the robustness of our findings. 
Third, we were able to study extreme differences in thyroid state in human subjects without 
thyroid autoimmunity. 
In conclusion, we demonstrated for the first time that thyroid state regulates numerous genes 
in human whole blood. Furthermore, we found that TH affects gene expression in platelets, 
which contributes to the understanding of thrombosis in hyperthyroidism. The overlap with 
previously reported DE-genes in muscle samples suggests that easily accessible whole blood 
samples potentially can be used as a proxy for other TRα-expressing tissues in humans. Future 
studies should explore if specific transcripts in whole blood can be useful biomarkers for tissue 
specific thyroid state.
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Supplemental Tables 3, 5 and 7 are available upon request.
Supplemental Table 1.
Gene Sense primer (5’-3’) Antisense primer (5’-3’)
ACTB GTA CAG GTC TTT GCG GAT GT CAC TCT TCC AGC CTT CCT TC
GAPDH GAG TCC TTC CAC GAT ACC AAA G GGT GTG AAC CAT GAG AAG TAT GA
RPS10 CTG GAT ACC CTC ATT GGT AAG G GCC ATG CAG TCT CTC AAG T
DDIT4 CAG GGC GTT TGC TGA TGA AC GGT TCG CAC ACC CAT TCA AG
EIF2AK1 CTT CTG CTC GCT CCA TTT CT TAC GTC CAG AGT GGG TAC TT
TUBB1 AAT GCT GTC CAT CGT CCC AG GCT GGA GAG AAT CAG CGT GT
PDE5A GCT AAC GAC TGT AGC TCT CTT G CCA GAA CAC GCA GAT GTA TGA
SNORD10 CTT CCC AGG GCT GTT GTC TG CTG CTC TCA GAG TAC AAA GAC TGA
RIOK3 CTT CAT TTG ATG CGG CAG TTA T CGA TCA ACC AGA CCT TTC CA
SNORA34 TGA CTG AAG ACC AGC AGT TGT AAC AGC CAA CAG ACC ACA GG
RPL35 TTG CCC GTG TTC TCA CAG TT GTC TTC TTA GGC CGC AGG TC
SNORA49 GCC TGT AAA GTG CTC TGG CA GCC CCA AAA GAA AAC AGC GT
CCNJL CAG GCA CCA GAG GGC AC GGC TCA TCC ATC ATC GCG TA
SPARC CCGCTTTTTCGAGACCTGTG ATCCGGTACTGTGGAAGGAGT
Supplemental Table 2. Characteristics of the patients in the discovery cohort. 
Subject Sex Ethnicity Age (yrs) BMI Co-morbidity
Number 
of RAI
Tg 
Off LT4
Tg
On LT4
1 female Iranian 21 22.3 Hypoparathyroidism 2 <0.9* <0.9*
2 male Dutch 66 23.6 DM type 1 1 <0.9* <0.9*
3 male Turkish 61 28.1 No 1 3.9 <0.9
4 female Dutch 48 33.4 No 1 1.9 <0.9
5 male Dutch 55 53.8 Chronic renal insuff
DM type 2
1 <0.9 <0.9
6 male Dutch 60 25.0 Hypoparathyroidism 1 73.0 1.10
7 female Moroccan 26 33.1 No 1 2.7* <0.9
8 female Turkish 37 24.8 Hypoparathyroidism 2 <0.9* <0.9
* anti-Tg positive
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Supplemental table 4. Characteristics and thyroid function tests of study participants in the validation 
cohort. Data are presented as median (IQR).
Off LT4 On LT4 P
TSH (mU/l) 64.6 (57.8-142.5) 0.016 (0.008-0.17) 0.008
Total T3 (nmol/l) 0.68 (0.54-0.81) 2.02 (1.74-2.17) 0.008
FT4 (pmol/l) 1.7 (1.2-2.0) 27.3 (23.5-30.2) 0.008
Age (years) 32.0 (26.5-53.0)
BMI (kg/m2) 28.4 (22.6-30.7)
Time between tests(wks) 18.7 (16.0-33.2)
Dose LT4 (µg/kg) 2.25 (1.97-2.45)
Sex 5 males, 4 females
Supplemental Table 6 Overlapping genes between differentially expressed genes (1.5 fold change; FDR 
0.05) in skeletal muscle and whole blood samples on versus off LT4 treatment 
2Log Ratio 
muscle
2Log Ratio 
whole blood Genes Description Location Type
0.79 0.72 ACSL1
acyl-CoA synthetase long-chain 
family member 1
Cytoplasm enzyme
0.62 0.67 BSG basigin (Ok blood group) Plasma 
Membrane
other
0.67 0.78 C1QA
complement component 1, q 
subcomponent, A chain
Extracellular 
Space
other
1.04 -0.70 COL4A4 collagen, type IV, alpha 4
Extracellular 
Space
other
0.92 0.69 DAB2
disabled homolog 2, mitogen-
responsive phosphoprotein 
(Drosophila)
Cytoplasm other
1.91 0.69 DNAJA4
DnaJ (Hsp40) homolog, 
subfamily A, member 4
Nucleus other
-0.59 -0.65 GAS5 growth arrest-specific 5 Unknown other
-0.75 -0.69 GPX7 glutathione peroxidase 7 Cytoplasm enzyme
1.12 0.72 MAP2K3
mitogen-activated protein kinase 
kinase 3
Cytoplasm kinase
-0.61 0.60 NUDT4
nudix (nucleoside diphosphate 
linked moiety X)-type motif 4
Cytoplasm
phospha-
tase
-0.62 -0.64 PER1 period homolog 1 (Drosophila) Nucleus other
-0.68 0.80 RAPH1
Ras association (RalGDS/AF-6) 
and pleckstrin homology domains 
1
Plasma 
Membrane
other
0.71 -0.60 SBK1 SH3-binding domain kinase 1 Cytoplasm kinase
0.60 0.59 SCYL2 SCY1-like 2 (S. cerevisiae) Cytoplasm other
0.97 0.82 SEC14L5 SEC14-like 5 (S. cerevisiae) Cytoplasm other
0.87 0.61 SERPINB1
serpin peptidase inhibitor, clade B 
(ovalbumin), member 1
Cytoplasm other
116 | Chapter 7
Supplemental Table 6 Overlapping genes between differentially expressed genes (1.5 fold change; FDR 
0.05) in skeletal muscle and whole blood samples on versus off LT4 treatment (Continued)
2Log Ratio 
muscle
2Log Ratio 
whole blood Genes Description Location Type
0.67 0.89 SLC14A1
solute carrier family 14 (urea 
transporter), member 1 (Kidd 
blood group)
Plasma 
Membrane
trans-
porter
0.80 0.99 SPARC
secreted protein, acidic, cysteine-
rich (osteonectin)
Extracellular 
Space
other
0.95 1.08 STON2 stonin 2 Cytoplasm other
1.01 0.61 TNFSF10
tumor necrosis factor (ligand) 
superfamily, member 10
Extracellular 
Space
cytokine
-0.79 0.62 ZAK
sterile alpha motif and leucine 
zipper containing kinase AZK
Cytoplasm kinase
0.73 0.82 FSTL1 Follistatin-Like 1
Extracellular 
Space
myokine
0.59 0.85 PCSK6
Proprotein Convertase Subtilisin/
Kexin Type 6
Cytoplasm enzyme
-0.70 1.04 MFAP3L
microfibrillar-associated protein 
3-like
Plasma 
Membrane
kinase
1.54 0.61 MAFB
v-maf musculoaponeurotic 
fibrosarcoma oncogene homolog 
B (avian)
Nucleus
tran-
scription 
factor
0.61 0.78 SLC22A4
solute carrier family 22 (organic 
cation/ergothioneine transporter), 
member 4
Plasma 
Membrane
trans-
porter
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Hypothyroidism is one of the most common endocrine disorders with a prevalence of  between 
0.2% and 5.3% in Europe, depending on the definition used (1). Hypothyroid symptoms 
include cold intolerance, constipation, bradycardia and weight gain. In contrast, patients with 
hyperthyroidism complain of sweating, palpitations and weight loss. These clinical effects of 
alterations in thyroid state arise from changes in thyroid hormone action at the cellular level. 
The standard treatment for primary hypothyroidism is substitution with synthetic levothyroxine 
(LT4). The peripheral conversion of LT4 to the biologically active thyroid hormone T3 makes 
it possible to achieve normal circulating T3 concentrations. In contrast, in euthyroid patients 
about 20% of circulating serum T3 is directly derived from thyroidal secretion. In a subset 
(~10-15%) of patients, symptoms of hypothyroidism persist despite serum thyroid hormone 
concentrations within the laboratory reference range (2, 3). The reasons and solutions for 
these persisting symptoms are still a matter of debate, but these persisting symptoms can be 
very frustrating for both patients and doctors. Therefore, it is crucial that the pathophysiology 
underlying persisting complaints in patients with adequately treated hypothyroidism should 
be elucidated in order to improve treatment of hypothyroidism. As a first step, the physiological 
and molecular effects of well-known clinical features due to changes in thyroid state should 
be understood.  
Patients with differentiated thyroid cancer (DTC) are exposed to different thyroid states as 
part of their treatment. These patients are subject to severe hypothyroidism before radioactive 
iodine (RAI) therapy to stimulate radioactive iodine uptake by malignant tissues, whereas they 
have relatively high thyroid hormone concentrations afterwards when receiving substitution 
therapy with LT4 to suppress TSH (<0.1 mIU/L). Since large changes in thyroid hormone 
levels are observed, this patient group offers the unique opportunity to observe the effect of 
extreme differences in thyroid state on physiological parameters within the same subject.
In the first part (chapter 2 and 3) of this thesis the effects of thyroid hormone on different 
organs was assessed to get a better understanding of physiological effects of thyroid hormone. 
In the second part (chapter 4 and 5), the association of autoimmune thyroid disease with 
mood disorders was studied as well as the association of thyroid function tests with quality of 
life (QoL). In the third part (chapter 6 and 7), we searched for new biomarkers of thyroid 
state.    
Physiological effects of thyroid hormone
To get a better understanding of the clinical effects of thyroid hormone, the consequences 
of hypothyroidism in several target tissues was studied. In chapter 2, the effect of thyroid 
hormone on renal concentrating ability and renal function was studied in patients with DTC off 
and on LT4 treatment. Serum creatinine levels were significantly higher in our patients during 
hypothyroidism than during LT4 treatment and, correspondingly, eGFR was significantly 
lower during hypothyroidism. This is a well-known consequence of hypothyroidism (4-
124 | Chapter 8
6). However, in contrast with previously published studies in rats (7) and humans with 
autoimmune hypothyroidism/ myxoedema (8, 9), we could not detect an impairment of 
urinary concentrating ability during severe short-term hypothyroidism in our patients. It has 
to be mentioned that our LT4 treated patients received a high dosage of LT4 in order to reach 
TSH-suppression and that the urine osmolality was somewhat low in both thyroid states (< 
1000 mOsmol/kg). One could speculate that there could have been a concentrating defect in 
both thyroid states precluding a statistical significant difference in urine osmolality. Future 
studies should include an euthyroid control group to rule out this possibility. 
In chapter 3, the effect of thyroid hormone on the microcirculation and on the 
macrocirculation was studied in DTC patients off and on LT4 treatment. Normal thyroid 
hormone levels are required to maintain normal cardiovascular function and important 
changes in cardiac structure and function have been reported in patients with overt and 
subclinical hypothyroidism (10). Although effects of thyroid hormone on the macrocirculation 
have been studied extensively, very little is known of the effects of TH on the microcirculation 
in humans (11, 12). In hamster cheek pouch, topical application of T3 induced dose-dependent 
dilation of arterioles within 2 minutes of administration (13). This T3-induced dilation was 
countered by the inhibition of nitric oxide (NO) synthase with NG-nitro-L-arginine methyl-
ester (L-NAME), suggesting that the direct effects of T3 on the in vivo microcirculation are 
mediated by NO through non-genomic mechanisms of action. After stimulation with nitric 
oxide, soluble guanylyl cyclase generates cyclic guanosine monophosphate (cGMP), which 
induces vasodilation (14). Interestingly, this is in line with findings from chapter 7. In chapter 
7, we performed next generation RNA sequencing on whole blood samples from another 
cohort of DTC patients in different thyroid states. The genes GUCY1A3 and GUCY1B3, which 
encode for the alpha and beta subunits of the enzyme soluble guanylyl cyclase respectively, 
were significantly upregulated by thyroid hormone. In addition, we found that the biological 
process vasodilation was 6.7 fold enriched by thyroid hormone (P value 0.02, not significant 
after correction for multiple testing). The genes in this biological process included PDE5A, 
which was significantly upregulated by thyroid hormone and encodes for a cGMP-binding 
phosphodiesterase. It is involved in the regulation of intracellular concentrations of cyclic 
nucleotides and is important for smooth muscle relaxation in the cardiovascular system (15). 
Although these genes were expressed in whole blood samples in our study, the findings might 
indicate that the same genomic effects of thyroid hormone occur in endothelial cells of blood 
vessels, although this needs to be confirmed in future studies. 
Given all these indications that thyroid hormone affects the vasculature, we hypothesized 
that differences in thyroid states would also affect the microcirculation. However, we were 
not able to demonstrate alterations in the sublingual microcirculation, assessed with a video 
microscope, in patients on and off LT4 treatment, although several well-known effects on 
heart rate, pulse pressure, systemic vascular resistance, and peripheral perfusion were 
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observed. The observed alterations in peripheral perfusion are likely to be mediated by effects 
of thyroid hormone on thermoregulation via the skin. In hypothyroidism, the reduced central 
thermogenesis is partially compensated by cutaneous vasoconstriction, which might have 
accounted for the observed decrease in peripheral perfusion in our patients (16, 17). The 
sublingual (central) microcirculation is not involved in thermoregulation, which may explain 
why no significant changes in the sublingual microcirculation were observed. 
Cognitive effects of thyroid hormone
As was mentioned above, despite adequate restoration of biochemical euthyroidism with 
LT4 replacement therapy, a substantial number of patients (~10-15 %) display significant 
impairment of psychological well-being and show decrements in health status (2, 3, 18, 
19). It has been speculated that the presence of associated autoimmune diseases or thyroid 
autoimmunity per se may also account for these persisting symptoms and for the often 
reported depressive symptoms (20, 21). It has been shown that subjects with thyroid 
autoimmunity, who are still euthyroid, have a higher risk to develop mood disorders (22). This 
finding, in combination with several other findings that were mentioned in the introduction of 
this thesis, suggests that there might be a shared immune pathogenesis for both autoimmune 
thyroid disease (AITD) and mood disorders. To explore the link between AITD and mood 
disorders, we determined 5 growth and differentiation factors that have repeatedly been 
shown to be abnormally expressed in the circulation of mood disorder patients and that are 
capable of influencing immune and/or neuronal cell growth in chapter 4 (23-25). These 
factors were studied in the serum of subjects from the Amsterdam AITD cohort (euthyroid 
females with at least one first or second degree relative with AITD) and were combined with 
levels of previously assessed immune factors (26). A distinct pattern of four inter correlating 
immune factors preceded TPO-Ab seroconversion in the next 5 years. This opens avenues for 
developing assays for the detection of individuals at risk for thyroid autoimmunity. However, 
this would only be helpful when one would be able to stop the autoimmune process and when 
thyroid dysfunction could be prevented.
Brain-derived neurotrophic factor (BDNF) levels were significantly lower in sera of the 
subjects from the Amsterdam AITD cohort than in healthy controls, while Insulin-like 
Growth Factor-Binding Protein 2 (IGFBP-2) and Epidermal Growth Factor (EGF) levels were 
significantly higher in the subjects. It has been demonstrated that BDNF levels are decreased 
in patients with a major depressive disorder and are also associated with clinical changes in 
depression (27). Unfortunately, we were not able to assess the association between the levels 
of these growth and differentiation factors and the mood state of the relatives. It would be very 
interesting to study the growth and differentiation factors in AITD patients with persisting 
symptoms, and to assess the association with these symptoms.  
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However, after thyroidectomy, cured patients with DTC on LT4 replacement therapy have 
also been shown to have an impaired QoL although they are not affected by an autoimmune 
disease (28, 29). This suggests that autoimmunity cannot be the only explanation for the 
persisting symptoms in treated hypothyroid  patients. Another explanation might be the 
inadequacy of LT4 treatment to restore physiological T4 and T3 concentrations in serum 
and tissues (30-32). Studies in hypothyroid rats have demonstrated that LT4 monotherapy is 
not able to normalize T4 and T3 concentrations in all tissues (33). Also, it remains unknown 
whether other endogenous thyroid hormone metabolites with T3-agonistic or antagonistic 
activities, like 3,5-T2, might play a role in the persisting symptoms and decreased QoL among 
hypothyroid patients. Therefore, in chapter 5, we performed a cross-sectional study in 
(mostly) cured athyreotic DTC patients on LT4 monotherapy to study the association between 
extensive thyroid function tests and QoL. Health-related QoL (RAND-36), thyroid specific QoL 
(ThyPRO) and fatigue (Multidimensional Fatigue Inventory) were assessed. We confirmed that 
health-related QoL was impaired in our patients compared with a Dutch reference group (34). 
Multiple linear regression analyses did not show any association between QoL and the different 
TFTs, including T4/T3 and 3,5-T2/T3 ratios reflecting peripheral metabolism. Therefore, our 
data do not support the hypothesis that complaints of fatigue and/or impaired well-being 
in hypothyroid patients on LT4 therapy are due to relatively low levels of serum T3 because 
of a lack of endogenous T3 secretion by the thyroid gland or to altered concentrations of T4 
metabolites. Furthermore, our data do not support therapy with liothyronine (T3) in patients 
with persisting complaints since we could not find an association with T3 concentrations and 
T4/T3 ratio and QoL. Since most of our patients were treated with supraphysiological LT4 
doses, we cannot rule out that there might be a relationship between T3 levels and QoL in 
patients treated with physiological LT4 doses, although subgroup analysis in our study did 
not demonstrate this. However, health-related QoL and years since diagnosis showed some 
relation and since similar results have been reported for duration of cure in other cohorts of 
DTC patients (28), QoL seems to improve when time since diagnosis increases. This message 
is important to convey to patients, since it will give them some hope for improvement of their 
complaints in the future. 
Search for new biomarkers of tissue-specific thyroid state
Serum TSH concentrations reflect the pituitary feedback to serum levels of thyroid hormone 
and is used in clinical practice to monitor LT4 treatment. Several studies have however shown 
that serum TSH may not always be an appropriate marker in hypothyroid patients under LT4 
therapy and that normal serum TSH levels in patients receiving levothyroxine strictly only 
reflect pituitary euthyroidism (35-37). For this reason, novel markers representing tissue 
thyroid state are needed. In Chapter 6, we studied if microRNAs in serum are regulated by 
thyroid state in a cohort of DTC patients. Previously, we reported on gene expression profiles 
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in skeletal muscle of hypothyroid patients off and on LT4 therapy and found a large down-
regulation in expression of some pri-miRNAs (38). It has been shown that miRNAs are present 
in the circulation (39) and have been associated with a variety of diseases (40). We therefore 
hypothesized that miRNA profiles in serum could also be influenced by thyroid state, and 
that miRNAs derived from different tissues potentially reflect tissue-specific differences in 
thyroid states. A magnetic bead capture system was used to isolate 384 miRNAs from serum. 
Subsequently, the TaqMan Array Card 3.0 platform was used for profiling. Unfortunately, a 
paired analysis did not demonstrate any significantly different expressed miRNA off and on 
LT4 treatment. In chapter 6, several possible explanations for these findings are provided. 
Our method might have been not sensitive enough to assess small differences in expression. 
However, only miRNAs that are extremely up- or downregulated will be suitable as clinical 
biomarkers and we certainly did not find such a miRNA in our selection of miRNAs. Of course, 
we cannot rule out that other miRNAs, which were not on the array card, are regulated by 
thyroid hormone in serum. 
As was mentioned in the introduction, genomic actions of thyroid hormone are mediated by 
binding to nuclear T3 receptors, which regulate transcription of target genes (41). Thyroid 
hormone responsive genes have also been identified in multiple human tissues, including 
for example liver, muscle, skin fibroblasts and adipocytes (38) (42, 43). However, to study 
the effects of thyroid hormone on gene expression in human tissues, easy accessible tissues 
would ideally be available, like blood samples. Therefore, we performed next generation RNA 
sequencing in whole blood samples from DTC patients off and on LT4 treatment (chapter 7). 
We detected 1227 differentially expressed (DE) genes of which 486 genes had a fold-change 
above 1.5. As we confirmed that the whole blood samples contained mainly TRα expressing 
cells our results presumably reflect the effect of thyroid hormone on gene expression via the 
TRα receptor. A significant overlap with the previously reported DE-genes in muscle samples 
(also a TRα-tissue) was found, which suggests indeed that easily accessible whole blood 
samples potentially can be used as a proxy for other tissues in humans. 
Weighted gene co-expression network analysis (WGCNA) was applied to identify thyroid 
state-related networks (modules). Two different modules that correlated significantly with 
thyroid state were identified. Both modules contained a lot of DE-genes from the standard 
differential expression analysis. The midnight blue module, which correlated negatively with 
thyroid state, contained numerous small nucleolar RNAs (snoRNAs). As the relationship 
between snoRNAs and thyroid hormone has not been reported before, further studies are 
needed to understand the consequences of this finding. Gene ontology analysis of the genes 
in the blue module, which correlated positively with thyroid hormone, revealed a 4 fold 
enrichment of the biological process hemostasis. This process was also significantly enriched 
in the 486 DE-genes from the standard DE-analysis. It is well known that hyperthyroidism 
increases the risk of thrombosis and that several coagulation factors are upregulated by 
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thyroid hormone (44-46). Our study now demonstrates an effect of thyroid hormone on 
gene transcription in platelets. Several genes (e.g. P2RY12, PF4) involved in coagulation and 
hemostasis were upregulated by thyroid hormone. P2RY12 is a G-protein coupled receptor, 
which plays a crucial role in thrombus formation (47). P2RY12 inhibitors, such as Clopidogrel, 
have antithrombotic effects. It would be interesting to study if the amount of expression of 
P2RY12 predicts the risk of developing thrombosis in patients with hyperthyroidism and if 
patients with severe and difficult to control hyperthyroidism should temporarily be treated 
with P2RY12 inhibitors.
Conclusions and future directions
The studies presented in this thesis provide more insights into the physiological effects of 
thyroid hormone on different tissues, although we did not unravel the mechanism behind 
persistent complaints in patients with thyroid dysfunction yet. Future studies are warranted to 
study the effects of other thyroid hormone metabolites on tissues and on QoL. Some products 
of peripheral thyroid hormone metabolism, like thyronamines (TAMs), were previously 
considered as inactive breakdown products. However, several reports have recently shown that 
they may have relevant biological effects as well (48, 49). The structure of the thyronamines 
differs from T4 and deiodinated thyroid hormone derivatives by the absence of a carboxylate 
group on the alanine side chain. 3-Iodothyronamine (T1AM) and its metabolite T0AM have 
been detected in sera of humans (48, 50, 51). Pharmacological administration of 3-T1AM 
has been shown to result in dose-dependent reversible effects on body temperature, cardiac 
function, energy metabolism, and neurological functions (52-55). However, the physiological 
relevance of these actions is still unclear. Furthermore, since large differences of 3-T1AM 
concentrations in human serum have been reported measured by liquid chromatography-
mass spectrometry (LC-MS/MS) versus a monoclonal antibody-based immunoassay, one 
should be very careful with interpreting the results of these studies. In chapter 5, we studied 
the association between QoL and thyroid function tests cross-sectional in athyreotic patients. 
A prospective study in patients, before and after thyroidectomy, assessing the association 
between QoL and a more extensive thyroid hormone profile (including TAMs) is needed. It is 
also important to include patients with benign thyroid disease (e.g. goiter, Graves’ disease) to 
exclude an effect of having a malignancy on QoL. 
In addition, the observed aberrancies in hematopoietic/ neuronal growth and differentiation 
factors reported in chapter 4 need to be studied in patients who have already developed 
AITD. It would be very interesting to measure the growth and differentiation factors in AITD 
patients on LT4 substitution therapy, with and without persisting symptoms, and to assess the 
association between the growth and differentiation factors with these symptoms. 
Although, we did not discover a new biomarker for tissue-specific thyroid state yet, we detected 
numerous genes which are regulated by thyroid hormone in human whole blood. Our results 
8General discussion | 129
demonstrate the power of untargeted approaches to detect novel pathways of thyroid hormone 
action. Since we found several genes in whole blood samples that were also regulated by 
thyroid hormone in human skeletal muscle samples, future studies should explore if specific 
transcripts in whole blood can be useful biomarkers for certain thyroid-related endpoints. 
Finally, other technologies have emerged to detect new biomarkers. Recently, a plasma 
proteome and metabolome characterization (OMICS approach) of an experimental human 
thyrotoxicosis model detected 65 metabolites and 63 proteins which were associated with 
serum FT4 (56). A subset of 15 molecules allowed a good prediction of thyroid hormone 
function (AUC=0.86) without prior information on TSH or FT4 levels. It would be interesting 
to use these technologies in hypothyroid conditions as well. 
This thesis introduces several important approaches in understanding the biological relevance 
of thyroid hormone replacement therapy and, hopefully, will stimulate further research to 
unravel the mechanism behind persistent complaints in patients with thyroid dysfunction. 
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Summary
Thyroid hormone affects virtually all cells and tissues in the body. The thyroid produces 
mainly T4 (thyroxine) which is an inactive form of thyroid hormone. T4 can be converted 
by deiodinases into the biologically active thyroid hormone, T3 (triiodothyronine). Genomic 
actions of thyroid hormone are mediated by binding of T3 to nuclear T3 receptors, which 
regulates transcription of target genes. Clinical effects of alterations in thyroid state arise 
from changes in thyroid hormone at the cellular level. Hypothyroid symptoms include 
cold intolerance, constipation, bradycardia and weight gain. In contrast, patients with 
hyperthyroidism complain of sweating, palpitations and weight loss. The standard treatment 
of hypothyroidism is substitution with synthetic levothyroxine (LT4). However, in a subset 
(~10-15%) of patients, symptoms of hypothyroidism persist despite serum thyroid hormone 
concentrations within the laboratory reference range. It is unclear what mechanisms underlie 
such symptoms. In this thesis several studies were dedicated to explore the physiological and 
molecular processes that may explain well-known clinical observations. 
The background of thyroid hormone synthesis, of thyroid hormone action and the regulation 
of serum thyroid hormone levels by the hypothalamus-pituitary-thyroid (HPT) axis are 
introduced in chapter 1. In addition, the outline of this thesis, which consists of three major 
parts, is presented in this first chapter.
Part I: Physiological effects of thyroid hormone
The first part of the thesis includes 2 studies on the physiological effects of thyroid hormone 
on target tissues/organs. In chapter 2, the effect of thyroid hormone on renal concentrating 
ability was studied in 9 patients off and on levothyroxine (LT4) treatment after a water and food 
deprivation test of 14 hours. We used serum and urine samples of patients with differentiated 
thyroid cancer (DTC) because they are subject to severe hypothyroidism before radioactive 
iodine therapy to stimulate radioactive iodine uptake by malignant tissues, whereas they 
have relatively high thyroid hormone concentrations afterwards when receiving substitution 
therapy with LT4 in order to reach TSH suppression. Our study confirmed the well-known 
effects of thyroid hormone on serum creatinine concentrations but could not demonstrate a 
significant difference in urine osmolality nor in serum osmolality on and off  LT4 treatment.  
In chapter 3 a fully integrated assessment of macrocirculation and microcirculation was 
performed in 10 DTC patients off and on LT4 treatment. A handheld video microscope was 
used to visualize the sublingual microcirculation. Peripheral perfusion was assessed by several 
non-invasive measurements, such as Tskin-diff and the peripheral perfusion index (PFI). 
In addition, transthoracic echocardiography was performed to assess alterations in cardiac 
function. Several well-known effects of thyroid hormone on end diastolic volume and stroke 
volume and on pulse pressure and heart rate were confirmed. The increase in Tskin-diff 
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during hypothyroidism and the decreases in PFI indicated a decrease in peripheral perfusion. 
However, we could not demonstrate significant alterations in the microcirculation in different 
thyroid states. 
Part II: Cognitive effects of thyroid hormone
In the second part of this thesis, the link between autoimmune thyroid disease (AITD) and 
mood disorders was explored (chapter 4) and the association between thyroid hormones 
and quality of life (QoL) was studied (chapter 5). To study the link between AITD and mood 
disorders several growth and differentiation factors were determined that have repeatedly 
been shown to be abnormally expressed in the circulation of mood disorder patients and that 
are capable of influencing immune and/or neuronal cell growth (chapter 4). We studied 
64 TPO-Ab-negative females with at least 1 first- or second-degree relative with AITD, 32 of 
whom did and 32 who did not seroconvert to TPO-Ab positivity in 5-year follow-up. Subjects 
were compared with 32 healthy controls. We found that relatives of AITD patients show 
aberrant serum levels of 4 hematopoietic/neuronal growth factors  similar to the aberrancies 
found in mood disorder patients. This might suggest that shared growth and differentiation 
defects in both the hematopoietic and neuronal system may underlie thyroid autoimmunity 
and mood disorders. 
In chapter 5, the association between extensive thyroid function tests and QoL was assessed 
in 143 athyreotic DTC patients on LT4 replacement therapy. Health-related QoL (RAND-
36), thyroid specific QoL (ThyPRO) and fatigue (Multidimensional Fatigue Inventory) were 
assessed, and their association with thyroid function tests was studied. Health-related QoL 
was impaired in our patients compared with a Dutch reference group. However, we did not 
find any association between TFTs, including 3,5-T2 concentrations and T4/T3 ratios, and 
QoL within our study group. Our data do not provide evidence that a slight increase in dose 
improves fatigue or well-being in hypothyroid patients on LT4 therapy.
Part III: Search for new biomarkers of tissue-specific thyroid state
In the third part of this thesis (chapters 6 and 7), we searched for new biomarkers of thyroid 
state. In Chapter 6, we studied for the first time if microRNAs in serum are regulated by 
thyroid state in 13 DTC patients off and on LT4. The expression of 384 microRNAs was 
assessed with a TaqMan MicroRNA Array. The generated selected serum miRNA profile did 
not reveal new biomarkers for thyroid state.  
In chapter 7, next generation RNA sequencing was performed in whole blood samples in a 
cohort of 8 other DTC patients on and off LT4 treatment. We demonstrated that numerous 
genes are regulated in different thyroid states. As we confirmed that the whole blood samples 
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contained mainly TRα expressing cells our results presumably reflect the effect of thyroid 
hormone on gene expression via the TRα receptor. A significant overlap with previously 
reported differentially expressed genes in muscle samples was observed, which suggests 
that easily accessible whole blood samples potentially can be used as a proxy for other 
tissues in humans. In addition, it was found that thyroid hormone affects gene expression 
in platelets, which might explain the reported increased risk of thrombosis in patients with 
hyperthyroidism. 
In chapter 8, the results which are presented in this thesis, are discussed and recommendations 
for future studies are suggested. 
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Samenvatting
De schildklier is een klein vlindervormig orgaan dat zich voor het schildklierkraakbeen 
in de nek bevindt. De schildklier produceert hoofdzakelijk T4 (thyroxine), hetgeen een 
inactieve vorm van schildklierhormoon is. T4 kan door speciale enzymen (dejodases) 
worden omgezet in het biologisch actieve schildklierhormoon T3 (trijodothyronine). Het 
belangrijkste werkingsmechanisme van schildklierhormoon verloopt via binding van T3 
aan de T3-receptoren in de celkern. Wanneer T3 bindt aan zijn receptor, kunnen vervolgens 
schildklierhormoongevoelige genen worden afgelezen.
Schildklierhormoon beïnvloedt vrijwel alle cellen en weefsels in het lichaam. Hypothyreoïdie, 
te weinig schildklierhormoon, kan leiden tot koude-intolerantie, constipatie, moeheid en 
gewichtstoename. Patiënten met te veel schildklierhormoon, dat wil zeggen hyperthyreoïdie, 
hebben juist last van overmatig transpireren, hartkloppingen en gewichtsverlies. Patiënten 
met hypothyreoïdie worden behandeld met het synthetisch schildklierhormoon levothyroxine. 
Helaas blijft een deel van deze patiënten, ondanks dat hun schildklierhormoonwaarden in het 
bloed weer binnen de normaalwaarden zijn, klachten houden. De oorzaak hiervan wordt nog 
niet goed begrepen. In dit proefschrift proberen we dit probleem beter te begrijpen. Daarvoor 
is het van belang om de onderliggende mechanismen van de werking van schildklierhormoon 
op diverse weefsels beter te begrijpen. Hoofdstuk 1 geeft algemene informatie over de 
schildklierhormoonfysiologie en over de inhoud van dit proefschrift. Vervolgens is het 
proefschrift in drie delen opgedeeld.
Deel I: Fysiologische effecten van schildklierhormoon
In dit deel van het proefschrift worden fysiologische effecten van schildklierhormoon op 
doelorganen beschreven. In hoofdstuk 2 wordt het effect van schildklierhormoon op het 
concentrerend vermogen van de nier en nierfunctie onderzocht. We hebben dit in 9 patiënten 
met goed gedifferentieerd schildkliercarcinoom (schildklierkanker) onderzocht. Deze 
patiënten hadden vanwege een behandeling met radioactief jodium eerst verlaagde en daarna 
normale schildklierhormoonconcentraties in hun bloed. Voorafgaand aan de behandeling 
met radioactief jodium dienden deze patiënten te stoppen met het innemen van hun 
schildklierhormoontabletten. Hierdoor steeg de concentratie van het schildklier stimulerend 
hormoon (TSH), dat de opname van radioactief jodium in de tumorcellen bevordert.  Alle 
patiënten hebben op twee momenten (tijdens hypothyreoïdie en tijdens behandeling met 
schildklierhormoon) 14 uur lang gevast, waarna er bloed werd afgenomen en urine moest 
worden ingeleverd. Nader onderzoek hiervan bevestigde de reeds bekende effecten van 
schildklierhormoon op serum creatinine concentraties en op klaring. We vonden echter geen 
effect op het concentrerend vermogen van de nier.  
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In hoofdstuk 3 wordt het effect van schildklierhormoon op de microcirculatie beschreven 
in 10 patiënten met goed gedifferentieerd schildkliercarcinoom. Hiervoor werd een speciale 
videomicroscoop gebruikt, waarmee de werking van de vaatjes (de microcirculatie) onder 
de tong in beeld gebracht kon worden. Daarnaast werden nog diverse niet-invasieve andere 
technieken gebruikt om de perifere doorbloeding in kaart te brengen. Tevens werd de werking 
van het hart bestudeerd met echobeelden. De reeds bekende effecten van  schildklierhormoon 
op eind-diastolisch volume, slagvolume en polsfrequentie werden bevestigd. Verder zagen we 
tijdens hypothyreoïdie een toename in temperatuurverschil tussen vinger en onderarm en 
nam de perifere perfusie-index af. Dit wijst allemaal op een verminderde perifere perfusie 
en  koelere vingers. We konden echter geen significante veranderingen in de microcirculatie 
vinden tussen de verschillende schildklierhormooncondities.
Deel II: Cognitieve effecten van schildklierhormoon
In het tweede deel van dit proefschrift wordt in hoofdstuk 4 de link tussen auto-immuun 
schildklierziekten en stemmingsstoornissen onderzocht en in hoofdstuk 5 de associatie 
tussen schildklierhormoon en kwaliteit van leven. 
In hoofdstuk 4 worden diverse groei en differentiatie factoren beschreven, waarvan 
is aangetoond dat ze afwijkend tot expressie komen in het serum van patiënten met een 
stemmingsstoornis en waarvan bekend is dat ze de groei en ontwikkeling van immuun- en 
neuronale cellen beïnvloeden. Deze factoren werden bepaald in het serum van 64 gezonde 
vrouwelijke eerste of tweede graad familieleden van patiënten met een auto-immuun 
schildklierziekte. Van deze 64 vrouwen ontwikkelden 32 wel antistoffen en 32 geen antistoffen 
tegen TPO gedurende de 5 jaar van follow-up. Deze vrouwen werden vergeleken met 32 gezonde 
controles. Er werd een afwijkend gehalte vastgesteld in 4 groei- en differentiatiefactoren 
in de familieleden van patiënten met auto-immuun schildklierziekte, vergelijkbaar met de 
bevindingen in patiënten met stemmingsstoornissen. Dit suggereert dat dezelfde afwijkingen 
in groei en differentiatie van hematopoëse en neuronale cellen mogelijk ten grondslag liggen 
aan beide ziektebeelden. 
In hoofdstuk 5 wordt het verband beschreven tussen een uitgebreid schildklierhormoonprofiel 
en kwaliteit van leven in 143 patiënten met goed gedifferentieerd schildkliercarcinoom. 
Deze patiënten werden behandeld met een stabiele dosis van levothyroxine. De gezondheid-
gerelateerde kwaliteit van leven werd met de RAND-36 vragenlijst bestudeerd, schildklier-
specifieke kwaliteit van leven met de ThyPRO vragenlijst en vermoeidheid met de 
Multidimensionele Vermoeidheids Index. We constateerden dat gezondheid-gerelateerde 
kwaliteit van leven minder was in onze patiënten ten opzichte van een Nederlandse 
referentiegroep. We vonden in onze studiegroep echter geen associatie met diverse 
schildklierhormonen, inclusief 3,5-T2 concentraties en T4/T3 ratio’s. Onze bevindingen 
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bieden dan ook geen bewijs dat het aanpassen van de dosering levothyroxine leidt tot 
verbetering van vermoeidheid en welbevinden. 
Deel III: Zoektocht naar nieuwe biomarkers voor weefselspecifieke 
schildklierstatus
In het derde deel van dit proefschrift (hoofdstuk 6 en 7) wordt de zoektocht naar nieuwe 
biomarkers voor schildklierstatus beschreven. In hoofdstuk 6 wordt onderzocht of 
microRNA’s in serum worden gereguleerd door schildklierhormoon. Daarvoor werd de 
expressie van 384 microRNA’s gemeten met een TaqMan MicroRNA Array in het serum van 
13 patiënten met goed gedifferentieerd schildkliercarcinoom tijdens hypothyreoïdie en tijdens 
TSH-suppressie therapie. We vonden echter geen enkele significant verschillende microRNA. 
In hoofdstuk 7, worden de resultaten van next-generation RNA sequencing 
in volbloedmonsters van een cohort van 8 patiënten met goed gedifferentieerd 
schildkliercarcinoom met en zonder behandeling met levothyroxine beschreven. Er werd 
aangetoond dat vele genen worden gereguleerd door schildklierhormoon. Aangezien we 
hebben bevestigd dat cellen in volbloed met name de schildklierhormoon receptor alpha (TRα) 
bevat reflecteren onze resultaten met name het effect van schildklierhormoon via TRα. We 
vonden een significante overlap met de voorheen gerapporteerde differentieel tot expressie 
komende genen in spiermonsters van patiënten met schildkliercarcinoom. Dit suggereert dat 
makkelijk toegankelijke volbloedmonsters gebruikt zouden kunnen worden als een model om 
het effect van schildklierhormoon op andere weefsels te bestuderen. Daarnaast vonden we 
ook dat schildklierhormoon de genexpressie in trombocyten (bloedplaatjes) bevordert. Dit 
zou een verklaring kunnen zijn voor de verhoogde tromboseneiging die is waargenomen in 
patiënten met hyperthyreoïdie.
In hoofdstuk 8 tenslotte worden de resultaten van de diverse studies bediscussieerd en 
worden aanbevelingen gegeven voor toekomstig onderzoek. 
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A 33-year-old man was treated for acute lymphoblastic leukemia according to an intensive 
pediatric-inspired protocol with combination chemotherapy (1). At day 21 of his first 
chemotherapy course, he developed neutropenic fever. Blood cultures showed Candida 
albicans. The central venous catheter was removed, and iv fluconazole treatment was started 
for 14 days. At day 23, he developed a painful neck and palpitations. Ultrasound showed a 
diffusely enlarged hypoechogenic thyroid gland without nodules. Because of suspicion of 
a Candida thyroiditis, a fine-needle aspiration of the thyroid gland was performed, which 
revealed numerous yeast forms consistent with Candida (Figure 1), although cultures were 
negative. The treatment course with fluconazole was extended to 42 days. Thyroid function 
tests demonstrated hyperthyroidism (TSH = 0.012 mU/L; free T4 > 90 pmol/L), converting 
within 2 weeks into hypothyroidism (TSH = 16.3 mU/L; free T4 = 4.3 pmol/L). Levothyroxine 
treatment was then started and continued. At day 59, after bone marrow recovery, fever 
remitted in combination with a progressive painful cervical mass. Computed tomography 
showed a multiloculated abscess of the entire thyroid gland (Figure 2). Ultrasound-guided 
drainage was tried unsuccessfully, and ultimately surgical drainage of 250 mL of pus was 
performed, after which the abscess resolved. Blankophor staining demonstrated multiple 
fungal elements. Candida thyroiditis is a rare complication in immunocompromised patients 
with systemic Candida infections. Close monitoring is necessary to diagnose abscess formation 
in time (2). Microscopic examination of the fine-needle aspiration is a valuable diagnostic 
tool because cultures can remain negative, especially when systemic therapy has already been 
started (3, 4). Thyroid function should be closely monitored. 
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Figure 1. Grocott staining of the fine-needle aspiration showing yeast (magnification, ×40).
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Figure 2. A, Computed tomography (CT) of the neck during an episode of neutropenic fever shows diffuse 
enlargement of the thyroid gland (black arrow) and edematous swelling of soft tissues (white arrow). B, 
CT scan 3 weeks later showing multiple low-density areas (arrows) representing a large multiloculated 
abscess of 100 × 60 × 100 mm within the thyroid gland.
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